

# Michael Camilleri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/704614/publications.pdf>

Version: 2024-02-01

927  
papers

61,985  
citations

558

126  
h-index

2280

200  
g-index

1405  
all docs

1405  
docs citations

1405  
times ranked

25564  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of biochemical, microbial and mucosal mRNA expression in bile acid diarrhoea and irritable bowel syndrome with diarrhoea. <i>Gut</i> , 2023, 72, 54-65.	12.1	16
2	Associations of Habitual Dietary Intake With Fecal Short-Chain Fatty Acids and Bowel Functions in Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2022, 56, 234-242.	2.2	5
3	Selecting optimal patients with gastroparesis for G-POEM procedure. <i>Gut</i> , 2022, 71, 659-660.	12.1	7
4	Towards a new era with safer $\mu$ -opiate receptor analgesia. <i>Gut</i> , 2022, 71, 1-2.	12.1	3
5	Increased Fecal Bile Acid Excretion in a Significant Subset of Patients with Other Inflammatory Diarrheal Diseases. <i>Digestive Diseases and Sciences</i> , 2022, 67, 2413-2419.	2.3	7
6	BAD on the Runs: Improved Diagnosis of Idiopathic Bile Acid Diarrhea. <i>Digestive Diseases and Sciences</i> , 2022, 67, 745-747.	2.3	1
7	Establishing Minimal Clinically Important Differences in Quality of Life Measures in Opioid-Induced Constipation. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 855-863.	4.4	6
8	Bile Acid Malabsorption in Patients with Neuroendocrine Tumors. <i>Digestive Diseases and Sciences</i> , 2022, 67, 2517-2525.	2.3	5
9	What to do about the leaky gut. <i>Gut</i> , 2022, 71, 424-435.	12.1	34
10	Epidemiology, Etiology, and Treatment of Gastroparesis: Real-World Evidence From a Large US National Claims Database. <i>Gastroenterology</i> , 2022, 162, 109-121.e5.	1.3	45
11	Severity of dysphagia is associated with hospitalizations and mortality in patients with Parkinson's disease. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14280.	3.0	9
12	Gastroparesis. <i>Gastroenterology</i> , 2022, 162, 68-87.e1.	1.3	37
13	Bile Acid Diarrhea in Adults and Adolescents. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14287.	3.0	15
14	Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience. <i>International Journal of Obesity</i> , 2022, 46, 555-563.	3.4	16
15	Impact of Bile Acid Diarrhea in Patients With Diarrhea-Predominant Irritable Bowel Syndrome on Symptoms and Quality of Life. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2083-2090.e1.	4.4	20
16	Guanylate cyclase-C agonists as peripherally acting treatments of chronic visceral pain. <i>Trends in Pharmacological Sciences</i> , 2022, 43, 110-122.	8.7	8
17	Gastrointestinal motility disorders in patients with multiple sclerosis: A single-center study. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14326.	3.0	7
18	Safety and Efficacy of Eluxadoline in Patients with Irritable Bowel Syndrome-Diarrhea With or Without Bile Acid Diarrhea: Open-Label Study. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3911-3921.	2.3	4

#	ARTICLE	IF	CITATIONS
19	2021 Workshop: Neurodegenerative Diseases in the Gut-Brain Axisâ€”Parkinson's Disease. <i>Gastroenterology</i> , 2022, 162, 1574-1582.	1.3	7
20	Single-center Clinical Experience of Diarrhea in Patients Treated With Sorafenib Shows Rare Development of Pancreatic Atrophy. , 2022, 1, 296-298.		0
21	Impact of elobixibat on serum and fecal bile acid levels and constipation symptoms in patients with chronic constipation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, , .	2.8	7
22	Bile Acid Diarrhea Is Associated With Increased Intestinal Permeability Compared With Irritable Bowel Syndrome-Diarrhea. <i>Gastroenterology</i> , 2022, 162, 1343-1345.e1.	1.3	5
23	Bile acid detergency: permeability, inflammation, and effects of sulfation. <i>American Journal of Physiology - Renal Physiology</i> , 2022, 322, G480-G488.	3.4	18
24	Pain in irritable bowel syndrome: Does anything really help?. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14305.	3.0	7
25	Fasting pyloric diameter and distensibility by functional endoluminal imaging probe in unседated healthy volunteers. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14386.	3.0	8
26	Update on the role of naldemedine in opioid-induced constipation in patients with chronic noncancer pain. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210786.	3.2	4
27	Rectal Evacuation Disorders in Patients Presenting With Chronic Functional Diarrhea. , 2022, 1, 549-552.		0
28	Differential mRNA expression in ileal and colonic biopsies in irritable bowel syndrome with diarrhea or constipation. <i>American Journal of Physiology - Renal Physiology</i> , 2022, 323, G88-G101.	3.4	6
29	Clinical trial: a singleâ€”centre, randomised, controlled trial of tradipitant on satiation, gastric functions, and serum drug levels in healthy volunteers. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 224-230.	3.7	4
30	Choosing G-POEM or other treatments for gastroparesis. <i>Gut</i> , 2022, 71, 2145-2146.	12.1	1
31	Effects of Heterozygous Variants in the Leptin-Melanocortin Pathway on Roux-en-Y Gastric Bypass Outcomes: a 15-Year Caseâ€”Control Study. <i>Obesity Surgery</i> , 2022, 32, 2632-2640.	2.1	15
32	Editorial: tradipitant has promise for treating gastroparesis but leaves gastric function aloneâ€”authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 542-543.	3.7	0
33	Comprehensive characterization of antral and pyloric contractions by high resolution manometry: applied physiology in suspected gastroparesis. <i>American Journal of Physiology - Renal Physiology</i> , 2022, 323, G255-G264.	3.4	7
34	Treatment of Irritable Bowel Syndrome Using Fecal Microbiota Transplantation: A Step Forward?. <i>Gastroenterology</i> , 2022, 163, 815-817.	1.3	3
35	Pharmacology, Clinical Effects, and Therapeutic Potential of Cannabinoids for Gastrointestinal and Liver Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1748-1758.e2.	4.4	19
36	FMT in IBS: a call for caution. <i>Gut</i> , 2021, 70, gutjnl-2020-321529.	12.1	7

#	ARTICLE	IF	CITATIONS
37	Audit of Gastrointestinal Manifestations in Patients with Loey's "Dietz Syndrome and Vascular Ehlers-Danlos Syndrome. Digestive Diseases and Sciences, 2021, 66, 1142-1152.	2.3	5
38	Gastroparesis Following Immune Checkpoint Inhibitor Therapy: A Case Series. Digestive Diseases and Sciences, 2021, 66, 1974-1980.	2.3	5
39	Epidemiology of gastroparesis: important answers and still more questions. Gut, 2021, 70, 631-632.	12.1	2
40	Ten Reasons to Think About Bile Acids in Managing Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2021, 15, 511-515.	1.3	4
41	Disturbances of Gastrointestinal Motility and the Nervous System. , 2021, , 217-234.		0
42	Pharmacological Treatments for Constipation and Opioid-Induced Constipation. , 2021, , .		0
43	Gastric dysmotility at the organ level in gastroparesis. , 2021, , 47-67.		0
44	A vision of the future for gastroparesis. , 2021, , 527-538.		0
45	Human Intestinal Barrier: Effects of Stressors, Diet, Prebiotics, and Probiotics. Clinical and Translational Gastroenterology, 2021, 12, e00308.	2.5	50
46	Every Breath Test You Take: Practical Advice on Breath Testing Used to Detect Small Intestinal Bacterial Overgrowth. Digestive Diseases and Sciences, 2021, 66, 331-333.	2.3	3
47	Markers of Bile Acid Metabolism in Pediatric Diarrhea Predominant Irritable Bowel Syndrome and Healthy Controls. Journal of Pediatric Gastroenterology and Nutrition, 2021, 72, 859-865.	1.8	8
48	Gastrointestinal motility disorders in neurologic disease. Journal of Clinical Investigation, 2021, 131, .	8.2	68
49	Reduced gastric accommodation in patients with Parkinson's disease: A case series. Neurogastroenterology and Motility, 2021, 33, e14143.	3.0	0
50	Diagnosis and Treatment of Irritable Bowel Syndrome. JAMA - Journal of the American Medical Association, 2021, 325, 865.	7.4	128
51	Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic. Obesity, 2021, 29, 662-671.	3.0	70
52	Gastric Sensory and Motor Functions and Energy Intake in Health and Obesity: Therapeutic Implications. Nutrients, 2021, 13, 1158.	4.1	21
53	Relationship of motor mechanisms to gastroparesis symptoms: toward individualized treatment. American Journal of Physiology - Renal Physiology, 2021, 320, G558-G563.	3.4	7
54	Differential mRNA Expression in Ileal Mucosal Biopsies of Patients With Diarrhea- or Constipation-Predominant Irritable Bowel Syndrome. Clinical and Translational Gastroenterology, 2021, 12, e00329.	2.5	5

#	ARTICLE	IF	CITATIONS
55	Su084 DIAGNOSING BILE ACID DIARRHEA IN PEDIATRIC IBS-D USING 48 HOURS FECAL BILE ACID TESTING. <i>Gastroenterology</i> , 2021, 160, S-609-S-610.	1.3	1
56	Gastric accommodation influences proximal gastric and total gastric emptying in concurrent measurements conducted in healthy volunteers. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, G759-G767.	3.4	15
57	A North American perspective on the ESNM consensus statement on gastroparesis. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14174.	3.0	6
58	Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK-906), a dopamine D <sub>2</sub> /D <sub>3</sub> receptor antagonist, in patients with gastroparesis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 267-280.	3.7	13
59	Editorial: finding the ideal prokinetic for gastroparesis—we are not there yet. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 212-213.	3.7	0
60	What is the leaky gut? Clinical considerations in humans. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2021, 24, 473-482.	2.5	18
61	Association of gastric emptying with postprandial appetite and satiety sensations in obesity. <i>Obesity</i> , 2021, 29, 1497-1507.	3.0	13
62	A Review of Irritable Bowel Syndrome—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 189.	7.4	0
63	Naldemedine Improves Patient-Reported Outcomes of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain in the COMPOSE Phase 3 Studies. <i>Journal of Pain Research</i> , 2021, Volume 14, 2179-2189.	2.0	6
64	Development and Validation of Test for “Leaky Gut”-Small Intestinal and Colonic Permeability Using Sugars in Healthy Adults. <i>Gastroenterology</i> , 2021, 161, 463-475.e13.	1.3	24
65	Turning Purple with Pain. <i>New England Journal of Medicine</i> , 2021, 385, 549-554.	27.0	3
66	New Developments in Prokinetic Therapy for Gastric Motility Disorders. <i>Frontiers in Pharmacology</i> , 2021, 12, 711500.	3.5	31
67	Beyond Metoclopramide for Gastroparesis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	4.4	5
68	New Drugs on the Horizon for Functional and Motility Gastrointestinal Disorders. <i>Gastroenterology</i> , 2021, 161, 761-764.	1.3	2
69	Intestinal chemosensitivity in irritable bowel syndrome associates with small intestinal TRPV channel expression. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1179-1192.	3.7	17
70	Gastric Motor Functions in Patients With Mood Disorders and Functional Gastroduodenal Symptoms. <i>Psychosomatic Medicine</i> , 2021, 83, 171-176.	2.0	2
71	Randomised study: effects of the 5-HT <sub>4</sub> receptor agonist felcisetrag vs placebo on gut transit in patients with gastroparesis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1010-1020.	3.7	21
72	International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. <i>Pharmacological Reviews</i> , 2021, 73, 310-520.	16.0	127

#	ARTICLE	IF	CITATIONS
73	Cohort Study in Parkinsonism. <i>Neurology: Clinical Practice</i> , 2021, 11, e407-e413.	1.6	9
74	Editorial: understanding IBS pathophysiology through “converging channels” of research”authors” reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1215-1216.	3.7	0
75	Liraglutide reduces attenuation coefficient as a measure of hepatic steatosis during 16 weeks' treatment in nondiabetic obese patients: A pilot trial. <i>JGH Open</i> , 2021, 5, 193-198.	1.6	6
76	Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. <i>Nature Genetics</i> , 2021, 53, 1543-1552.	21.4	96
77	Association of glucagon-like peptide 1 analogs and agonists administered for obesity with weight loss and adverse events: a systematic review and network meta-analysis. <i>EClinicalMedicine</i> , 2021, 42, 101213.	7.1	41
78	Review article: Elobixibat: a novel treatment for chronic constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 234-242.	3.7	14
79	GWAS of stool frequency provides insights into gastrointestinal motility and irritable bowel syndrome. <i>Cell Genomics</i> , 2021, 1, 100069.	6.5	15
80	Letter: elobixibatting for the long run”authors” reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 769-770.	3.7	0
81	Management of Gastroparesis.. <i>Gastroenterology and Hepatology</i> , 2021, 17, 515-525.	0.1	1
82	Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. <i>Gut</i> , 2020, 69, 74-82.	12.1	122
83	Canadian Association of Gastroenterology Clinical Practice Guideline on the Management of Bile Acid Diarrhea. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 24-41.e1.	4.4	40
84	Etiopathogenetic Mechanisms in Diverticular Disease of the Colon. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 9, 15-32.	4.5	33
85	Changes in Time of Gastric Emptying After Surgical and Endoscopic Bariatrics and Weight Loss: A Systematic Review and Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 57-68.e5.	4.4	61
86	Use of Treatments for Irritable Bowel Syndrome and Patient Satisfaction Based on the IBS in America Survey. <i>Gastroenterology</i> , 2020, 158, 786-788.e1.	1.3	33
87	Association between allelic variants in the glucagon-like peptide 1 and cholecystokinin receptor genes with gastric emptying and glucose tolerance. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13724.	3.0	4
88	Utility of the plasma pancreatic polypeptide response to modified sham feeding in diabetic gastroenteropathy and non-ulcer dyspepsia. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13744.	3.0	5
89	Management of functional constipation in children and adults. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 21-39.	17.8	216
90	GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1552-1563.	3.6	60

#	ARTICLE	IF	CITATIONS
91	Information- and Health-care Seeking Behaviors in Patients With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2840-2842.	4.4	5
92	Pretest and Post-test Probabilities of Diagnoses of Rectal Evacuation Disorders Based on Symptoms, Rectal Exam, and Basic Tests: a Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2479-2490.	4.4	20
93	Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 117-131.	8.1	108
94	The Role of Bile Acids in Chronic Diarrhea. <i>American Journal of Gastroenterology</i> , 2020, 115, 1596-1603.	0.4	48
95	Longitudinal Multi-omics Reveals Subset-Specific Mechanisms Underlying Irritable Bowel Syndrome. <i>Cell</i> , 2020, 182, 1460-1473.e17.	28.9	217
96	Irritable bowel syndrome. <i>Lancet, The</i> , 2020, 396, 1675-1688.	13.7	348
97	The benefit of elobixibat in chronic constipation is associated with faecal deoxycholic acid but not effects of altered microbiota. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 821-828.	3.7	19
98	Associations of gastric volumes, ingestive behavior, calorie and volume intake, and fullness in obesity. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 319, G238-G244.	3.4	7
99	Clinical Features and Associations of Descending Perineum Syndrome in 300 Adults with Constipation in Gastroenterology Referral Practice. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3688-3695.	2.3	10
100	Editorial: a need for glucose monitoring on prokinetic treatment with a ghrelin agonist in diabetic gastroparesis? Author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 546-547.	3.7	0
101	Sa1715 ELOBIXIBAT, ILEAL BILE ACID TRANSPORTER INHIBITOR, INCREASES FECAL BILE ACIDS IN PATIENTS WITH CHRONIC CONSTIPATION. <i>Gastroenterology</i> , 2020, 158, S-394-S-395.	1.3	1
102	Parkinson disease and the gut: new insights into pathogenesis and clinical relevance. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 673-685.	17.8	116
103	Randomised clinical trial: significant biochemical and colonic transit effects of the farnesoid X receptor agonist tropifexor in patients with primary bile acid diarrhoea. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 808-820.	3.7	30
104	Mo1785 INCREASED FECAL BILE ACID EXCRETION IN A MAJORITY OF PATIENTS WITH DIARRHEA ASSOCIATED WITH MICROSCOPIC COLITIS, ULCERATIVE COLITIS, CROHN'S DISEASE, AND QUIESCENT CELIAC DISEASE. <i>Gastroenterology</i> , 2020, 158, S-919-S-920.	1.3	1
105	A Pilot Study Examining the Effects of GLP-1 Receptor Blockade Using Exendin-(9,39) on Gastric Emptying and Caloric Intake in Subjects With and Without Bariatric Surgery. <i>Metabolic Syndrome and Related Disorders</i> , 2020, 18, 406-412.	1.3	2
106	Effects of dietary components on intestinal permeability in health and disease. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 319, G589-G608.	3.4	77
107	Irritable Bowel Syndrome: Straightening the road from the Rome criteria. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13957.	3.0	19
108	Food Residue During Esophagogastroduodenoscopy Is Commonly Encountered and Is Not Pathognomonic of Delayed Gastric Emptying. <i>Digestive Diseases and Sciences</i> , 2020, 66, 3951-3959.	2.3	19

#	ARTICLE	IF	CITATIONS
109	Physical activity is associated with accelerated gastric emptying and increased ghrelin in obesity. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13879.	3.0	10
110	Expanding criteria for slow colonic transit in patients being evaluated for chronic constipation by scintigraphy. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13878.	3.0	9
111	A smart toilet for personalized health monitoring. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 453-454.	17.8	10
112	Association between gastrointestinal phenotypes and weight gain in younger adults: a prospective 4-year cohort study. <i>International Journal of Obesity</i> , 2020, 44, 2472-2478.	3.4	16
113	Systematic review with meta-analysis: efficacy and safety of treatments for opioid-induced constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 37-53.	3.7	18
114	Gastrointestinal motility evaluation in children with orthostatic intolerance: Mayo Clinic experience. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13863.	3.0	1
115	“œlt ain’t over œ  till it’s over!â€•Risk mitigation strategies for patients with gastrointestinal diseases in the aftermath of the COVID-19 pandemic. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1117-1123.	2.8	12
116	Refractory Constipation. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 623-642.	2.2	10
117	Expanding the phenotypic spectrum of lipomatosis of the sciatic nerve: Early-onset colonic diverticular disease. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13917.	3.0	2
118	Reply. <i>Gastroenterology</i> , 2020, 158, 1842-1843.	1.3	0
119	Combined Fasting Serum C4 and Primary Bile Acids From a Single Stool Sample to Diagnose Bile Acid Diarrhea. <i>Gastroenterology</i> , 2020, 159, 1952-1954.e2.	1.3	28
120	Fecal Bile Acid Testing in Assessing Patients With Chronic Unexplained Diarrhea: Implications for Healthcare Utilization. <i>American Journal of Gastroenterology</i> , 2020, 115, 1094-1102.	0.4	21
121	Letter: the gluten-free diet as a bottom-up approach for irritable bowel syndrome. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 185-186.	3.7	1
122	Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1307, 171-192.	1.6	64
123	Polyethylene glycol-based laxatives for chronic constipation œ“ Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 110-111.	8.1	1
124	Effects of Colesevelam on Bowel Symptoms, Biomarkers, and Colonic Mucosal Gene Expression in Patients With Bile Acid Diarrhea in a Randomized Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2962-2970.e6.	4.4	27
125	Sex as a biological variable in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13802.	3.0	33
126	Canadian Association of Gastroenterology Clinical Practice Guideline on the Management of Bile Acid Diarrhea. <i>Journal of the Canadian Association of Gastroenterology</i> , 2020, 3, e10-e27.	0.3	16



#	ARTICLE	IF	CITATIONS
127	Ileo-colonic delivery of conjugated bile acids improves glucose homeostasis via colonic GLP-1-producing enteroendocrine cells in human obesity and diabetes. <i>EBioMedicine</i> , 2020, 55, 102759.	6.1	43
128	Actionable biomarkers: the key to resolving disorders of gastrointestinal function. <i>Gut</i> , 2020, 69, 1730-1737.	12.1	31
129	Clinical presentation and characteristics of pelvic floor myofascial pain in patients presenting with constipation. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13845.	3.0	1
130	Treating the pylorus in gastroparesis: The new riddle wrapped in the ultimate enigma?. <i>Gastrointestinal Endoscopy</i> , 2020, 91, 1300-1302.	1.0	9
131	Opiates, the Pylorus, and Gastroparesis. <i>Gastroenterology</i> , 2020, 159, 414-421.	1.3	14
132	Overall safety of relamorelin in adults with diabetic gastroparesis: Analysis of phase 2a and 2b trial data. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1139-1148.	3.7	26
133	Secretin effects on gastric functions, hormones and symptoms in functional dyspepsia and health: randomized crossover trial. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G635-G645.	3.4	8
134	Autonomic Nervous System Dysfunction and the Gastrointestinal Tract. , 2020, , 197-212.		0
135	Colonic Transit. , 2020, , 638-648.		0
136	Assessing the efficacy of peripherally acting mu-opioid receptor antagonists (PAMORAs) in the treatment of opioid-induced constipation. <i>Gut</i> , 2019, 68, 1133-1134.	12.1	4
137	The Challenges of Gastroparesis: Changing Study Design to Improve Clinical Care. <i>American Journal of Gastroenterology</i> , 2019, 114, 1-3.	0.4	2
138	Association between delayed gastric emptying and upper gastrointestinal symptoms: a systematic review and meta-analysis. <i>Gut</i> , 2019, 68, 804-813.	12.1	147
139	How does one choose the appropriate pharmacotherapy for pediatric patients with functional dyspepsia?. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1921-1924.	1.8	4
140	Insights on Obesity in Children and Adults: Individualizing Management. <i>Trends in Endocrinology and Metabolism</i> , 2019, 30, 724-734.	7.1	10
141	Targeting neurons in the gastrointestinal tract to treat Parkinson's disease. <i>Clinical Parkinsonism &amp; Related Disorders</i> , 2019, 1, 2-7.	0.9	18
142	Review article: biological mechanisms for symptom causation by individual FODMAP subgroups – the case for a more personalised approach to dietary restriction. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 517-529.	3.7	27
143	Relationship between symptoms during a gastric emptying study and intestinal chemosensitivity with daily symptoms. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13686.	3.0	14
144	856 – Assessment of the Impact of Introducing Fecal Bile Acid Diagnostic Test for Bile Acid Diarrhea in 250 Patients in Clinical Practice and on Prediction of Response to Bile Acid Sequestrants. <i>Gastroenterology</i> , 2019, 156, S-188-S-189.	1.3	2

#	ARTICLE	IF	CITATIONS
145	Hirschsprung disease: Insights on genes, penetrance, and prenatal diagnosis. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13732.	3.0	15
146	Letter to the Editor: “Defects in GLP-1 Response to an Oral Challenge Do Not Play a Significant Role in the Pathogenesis of Prediabetes” <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5106-5107.	3.6	0
147	Effects of Irritable Bowel Syndrome on Daily Activities Vary Among Subtypes Based on Results From the IBS in America Survey. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2471-2478.e3.	4.4	65
148	Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 831-844.	8.1	87
149	What’s in the pipeline for lower functional gastrointestinal disorders in the next 5 years?. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, G640-G650.	3.4	8
150	Sa1947 “ Randomized, Double-Blind, Placebo-Controlled Trial of Colesevelam in Patients with Bile Acid Diarrhea: Effects on Fecal Bile Acids, Colonic Transit, and Bowel Functions. <i>Gastroenterology</i> , 2019, 156, S-464-S-465.	1.3	1
151	Familial chronic megacolon presenting in childhood or adulthood: Seeking the presumed gene association. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13550.	3.0	8
152	Full-thickness evaluation from endoscopic rectal sampling: an important first step in tissue diagnosis of colonic dysmotility. <i>Gastrointestinal Endoscopy</i> , 2019, 89, 1248-1250.	1.0	0
153	Role for diet in normal gut barrier function: developing guidance within the framework of food-labeling regulations. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, G17-G39.	3.4	60
154	Increased fecal primary bile acids in multiple myeloma with engraftment syndrome diarrhea after stem cell transplant. <i>Bone Marrow Transplantation</i> , 2019, 54, 1898-1907.	2.4	1
155	Use of prucalopride in adults with chronic idiopathic constipation. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 579-589.	3.1	22
156	976 “ A Double-Blind, Randomized, Placebo-Controlled, Crossover, Multiple-Dose Study of Tropifexor, a Non Bile Acid Fxr Agonist, in Patients with Primary Bile Acid Diarrhea. <i>Gastroenterology</i> , 2019, 156, S-204-S-205.	1.3	5
157	Leaky gut: mechanisms, measurement and clinical implications in humans. <i>Gut</i> , 2019, 68, 1516-1526.	12.1	556
158	Small intestinal microbial dysbiosis underlies symptoms associated with functional gastrointestinal disorders. <i>Nature Communications</i> , 2019, 10, 2012.	12.8	168
159	GI Dysfunctions in Diabetic Gastroenteropathy, Their Relationships With Symptoms, and Effects of a GLP-1 Antagonist. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1967-1977.	3.6	16
160	Editorial: effects of vildagliptin on GLP-1 levels, gastric motor function and food intake. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1362-1363.	3.7	1
161	Physiology of the Colon and Its Measurement. , 2019, , 1676-1688.		3
162	Current Practice in the Diagnosis of Bile Acid Diarrhea. <i>Gastroenterology</i> , 2019, 156, 1233-1238.	1.3	50

#	ARTICLE	IF	CITATIONS
163	Effects of Proton Pump Inhibitors on Gastric Emptying and Symptoms: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2019, 156, 1650-1660.	1.3	114
164	Gastric accommodation measurements by single photon emission computed tomography and two-dimensional scintigraphy in diabetic patients with upper gastrointestinal symptoms. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13581.	3.0	19
165	Gastroparesis. , 2019, , 23-50.		3
166	Chronic Megacolon Presenting in Adolescents or Adults: Clinical Manifestations, Diagnosis, and Genetic Associations. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2750-2756.	2.3	16
167	Efficacy, long-term safety, and impact on quality of life of elobixibat in more severe constipation: Post hoc analyses of two phase 3 trials in Japan. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13571.	3.0	27
168	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 214.	4.4	0
169	Personalized management in functional gastrointestinal disorders based on genomics: hope at last or just feigned praise?. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 1756283X1882279.	3.2	0
170	Bile and fat excretion are biomarkers of clinically significant diarrhoea and constipation in irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 744-758.	3.7	32
171	The American neurogastroenterology and motility society gastroparesis cardinal symptom index daily diary (ANMS GCSI-DD): Psychometric evaluation in patients with idiopathic or diabetic gastroparesis. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13553.	3.0	14
172	PWE-076...Efficacy of Pharmacological Therapies in Patients with Irritable Bowel Syndrome with Diarrhoea: Network Meta-analysis. , 2019, , .		0
173	Colonic Manifestations and Complications Are Relatively Under-Reported in Systemic Sclerosis: A Systematic Review. <i>American Journal of Gastroenterology</i> , 2019, 114, 1847-1856.	0.4	19
174	Microbiome: In Search of Mechanistic Information and Relevance. <i>American Journal of Gastroenterology</i> , 2019, 114, 1014-1016.	0.4	4
175	Aquaporin Expression in Colonic Mucosal Biopsies From Irritable Bowel Syndrome With Diarrhea. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00019.	2.5	22
176	Characterization of Upper Gastrointestinal Symptoms, Gastric Motor Functions, and Associations in Patients with Diabetes at a Referral Center. <i>American Journal of Gastroenterology</i> , 2019, 114, 143-154.	0.4	49
177	Evaluation of Patients with Suspected Gastroparesis. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2019, 29, 39-54.	1.4	10
178	Audit of the diagnosis of rectal evacuation disorders in chronic constipation. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13510.	3.0	27
179	Gastrointestinal hormones and regulation of gastric emptying. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2019, 26, 3-10.	2.3	66
180	Comparison of mucosal impedance measurements throughout the esophagus and mucosal eosinophil counts in endoscopic biopsy specimens in eosinophilic esophagitis. <i>Gastrointestinal Endoscopy</i> , 2019, 89, 693-700.e1.	1.0	17

#	ARTICLE	IF	CITATIONS
181	Analysis of Fecal Primary Bile Acids Detects Increased Stool Weight and Colonic Transit in Patients With Chronic Functional Diarrhea. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 922-929.e2.	4.4	42
182	Implications of Pharmacogenomics to the Management of IBS. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 584-594.	4.4	7
183	Personalized medicine in functional gastrointestinal disorders: Understanding pathogenesis to increase diagnostic and treatment efficacy. <i>World Journal of Gastroenterology</i> , 2019, 25, 1185-1196.	3.3	21
184	Increased Prevalence of Rare Sucrase-isomaltase Pathogenic Variants in Irritable Bowel Syndrome Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1673-1676.	4.4	64
185	Allelic variant in the glucagon-like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13313.	3.0	37
186	Comparison of pH and motility of the small intestine of healthy subjects and patients with symptomatic constipation using the wireless motility capsule. <i>International Journal of Pharmaceutics</i> , 2018, 544, 158-164.	5.2	24
187	Advances in the diagnosis and classification of gastric and intestinal motility disorders. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 291-308.	17.8	168
188	Cardiovascular safety of prokinetic agents: A focus on drug-induced arrhythmias. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13302.	3.0	49
189	Effects of naloxegol on whole gut transit in opioid-naïve healthy subjects receiving codeine: A randomized, controlled trial. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13298.	3.0	12
190	Editorial: patient assessment of constipation symptoms (PACSYM) questionnaire has a minimal important difference. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 138-139.	3.7	0
191	Application of Pyridostigmine in Pediatric Gastrointestinal Motility Disorders: A Case Series. <i>Paediatric Drugs</i> , 2018, 20, 173-180.	3.1	41
192	Effects of Antidepressants on Gastric Function in Patients with Functional Dyspepsia. <i>American Journal of Gastroenterology</i> , 2018, 113, 216-224.	0.4	54
193	Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis. <i>Gastroenterology</i> , 2018, 154, 1309-1319.e7.	1.3	56
194	Open: Effects of NGM282, an FGF19 variant, on colonic transit and bowel function in functional constipation: a randomized phase 2 trial. <i>American Journal of Gastroenterology</i> , 2018, 113, 725-734.	0.4	29
195	Female-Specific Association Between Variants on Chromosome 9 and Self-Reported Diagnosis of Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2018, 155, 168-179.	1.3	55
196	COL1A1 Mutations Presenting as Descending Perineum Syndrome in a Young Patient With Hypermobility Syndrome. <i>Mayo Clinic Proceedings</i> , 2018, 93, 386-391.	3.0	4
197	Chronic nausea and vomiting: evaluation and treatment. <i>American Journal of Gastroenterology</i> , 2018, 113, 647-659.	0.4	64
198	Update on Bile Acid Malabsorption: Finally Ready for Prime Time?. <i>Current Gastroenterology Reports</i> , 2018, 20, 10.	2.5	34

#	ARTICLE	IF	CITATIONS
199	Malignancy and Meckel's diverticulum: A systematic literature review and 14-year experience at a tertiary referral center. <i>United European Gastroenterology Journal</i> , 2018, 6, 739-747.	3.8	26
200	Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders. <i>Gut</i> , 2018, 67, 1543-1552.	12.1	72
201	Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome. <i>Gut</i> , 2018, 67, 263-270.	12.1	120
202	Bile Acid Deficiency in a Subgroup of Patients With Irritable Bowel Syndrome With Constipation Based on Biomarkers in Serum and Fecal Samples. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 522-527.	4.4	57
203	Description of analytical method and clinical utility of measuring serum 7-alpha-hydroxy-4-cholesten-3-one (7aC4) by mass spectrometry. <i>Clinical Biochemistry</i> , 2018, 52, 106-111.	1.9	20
204	Large Meckel's Diverticulum and Dilated Adjacent Small Intestine Presenting With Intestinal Obstruction. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, A33.	4.4	2
205	Effects of Amitriptyline and Escitalopram on Sleep and Mood in Patients With Functional Dyspepsia. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 401-406.e2.	4.4	19
206	Advantages and Limitations of the Federal Adverse Events Reporting System in Assessing Adverse Event Reporting for Eluxadoline. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 336-338.	4.4	18
207	Insights on efficacious doses of PAMORA for patients on chronic opioid therapy or opioid-naïve patients. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13250.	3.0	5
208	Plausibility criteria for putative pathophysiological mechanisms in functional gastrointestinal disorders: a consensus of experts. <i>Gut</i> , 2018, 67, 1425-1433.	12.1	27
209	The content validity of the ANMS GCSI-DD in patients with idiopathic or diabetic gastroparesis. <i>Journal of Patient-Reported Outcomes</i> , 2018, 2, 61.	1.9	12
210	Current and future impact of clinical gastrointestinal research on patient care in diabetes mellitus. <i>World Journal of Diabetes</i> , 2018, 9, 180-189.	3.5	2
211	Management Options for Irritable Bowel Syndrome. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1858-1872.	3.0	76
212	New developments in the treatment of gastroparesis and functional dyspepsia. <i>Current Opinion in Pharmacology</i> , 2018, 43, 111-117.	3.5	85
213	Gastroparesis. <i>Nature Reviews Disease Primers</i> , 2018, 4, 41.	30.5	235
214	Elobixibat for the treatment of constipation. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 951-960.	3.0	28
215	Sex differences in NSAID-induced perturbation of human intestinal barrier function and microbiota. <i>FASEB Journal</i> , 2018, 32, 6615-6625.	0.5	39
216	Toward an effective peripheral visceral analgesic: responding to the national opioid crisis. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 314, G637-G646.	3.4	15

#	ARTICLE	IF	CITATIONS
217	Combination Therapies for Obesity. <i>Metabolic Syndrome and Related Disorders</i> , 2018, 16, 390-394.	1.3	35
218	Cannabinoids and gastrointestinal motility: Pharmacology, clinical effects, and potential therapeutics in humans. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13370.	3.0	62
219	Reproducibility of gastric emptying assessed with scintigraphy in patients with upper GI symptoms. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13365.	3.0	32
220	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1364.	4.4	0
221	Clinical measurement of gastrointestinal motility and function: who, when and which test?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 568-579.	17.8	44
222	Anal Achalasia: The Rat Tail Gas Sign. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, e124.	4.4	1
223	Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 537-547.	8.1	116
224	Endoscopic Sleeve Gastroplasty Alters Gastric Physiology and Induces Loss of Body Weight in Obese Individuals. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 37-43.e1.	4.4	222
225	Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2017, 152, 1042-1054.e1.	1.3	307
226	Rectal Gas Volume Measured by Computerized Tomography Identifies Evacuation Disorders in Patients With Constipation. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 543-552.e4.	4.4	26
227	Opioid analgesic use among patients presenting with acute abdominal pain and factors associated with surgical diagnoses. <i>Neurogastroenterology and Motility</i> , 2017, 29, e13000.	3.0	7
228	Biomarkers as a diagnostic tool for irritable bowel syndrome: where are we?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 303-316.	3.0	41
229	Dietary and pharmacological treatment of abdominal pain in IBS. <i>Gut</i> , 2017, 66, 966-974.	12.1	115
230	Rectal gas volume: Defining cutoffs for screening for evacuation disorders in patients with constipation. <i>Neurogastroenterology and Motility</i> , 2017, 29, e13044.	3.0	10
231	A working paradigm for the treatment of obesity in gastrointestinal practice. <i>Techniques in Gastrointestinal Endoscopy</i> , 2017, 19, 52-60.	0.3	7
232	A single-center, prospective, double-blind, sham-controlled, randomized study of the effect of a vibrating capsule on colonic transit in patients with chronic constipation. <i>Neurogastroenterology and Motility</i> , 2017, 29, e13034.	3.0	16
233	Gastrointestinal Complications of Obesity. <i>Gastroenterology</i> , 2017, 152, 1656-1670.	1.3	164
234	Bile acid disease. <i>Current Opinion in Gastroenterology</i> , 2017, 33, 189-195.	2.3	25

#	ARTICLE	IF	CITATIONS
235	Abdominal electroacupuncture demonstrates an increase in complete spontaneous bowel movements. Evidence-Based Medicine, 2017, 22, 101-101.	0.6	0
236	Potential mechanisms of effects of serum-derived bovine immunoglobulin/protein isolate therapy in patients with diarrhea-predominant irritable bowel syndrome. Physiological Reports, 2017, 5, e13170.	1.7	24
237	Upper gastrointestinal complications following ablation therapy for atrial fibrillation. Neurogastroenterology and Motility, 2017, 29, e13109.	3.0	22
238	Opioids in Gastroenterology: Treating Adverse Effects and Creating Therapeutic Benefits. Clinical Gastroenterology and Hepatology, 2017, 15, 1338-1349.	4.4	110
239	A Selection of the Best AGA Abstracts of DDW 2017. Gastroenterology, 2017, 153, e1-e5.	1.3	0
240	NGM282, Variant of FGF19, is a Gastric and Colonic Prokinetic and Stimulates Bowel Function in Patients with Functional Constipation: Phase 1B, Two-Dose, Placebocontrolled Study. Gastroenterology, 2017, 152, S1315.	1.3	2
241	Constipation-Predominant Irritable Bowel Syndrome Females Have Normal Colonic Barrier and Secretory Function. American Journal of Gastroenterology, 2017, 112, 913-923.	0.4	33
242	Polymorphisms of 5-HTT LPR and GRIK2 and Response to Antidepressant Treatment in Functional Dyspepsia: A Study from The Functional Dyspepsia Treatment Trial. American Journal of Gastroenterology, 2017, 112, 903-909.	0.4	11
243	POEMs for gastroparesis. Gastrointestinal Endoscopy, 2017, 85, 129-131.	1.0	12
244	Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: a systematic review and network meta-analysis. Gut, 2017, 66, 1611-1622.	12.1	132
245	Anniversary Tribute From the Editors of Clinical Gastroenterology and Hepatology. Clinical Gastroenterology and Hepatology, 2017, 15, 1823-1827.	4.4	0
246	Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. The Lancet Gastroenterology and Hepatology, 2017, 2, 890-899.	8.1	123
247	The Gastrointestinal Tract as an Integrator of Mechanical and Hormonal Response to Nutrient Ingestion. Diabetes, 2017, 66, 2729-2737.	0.6	30
248	Gastric Motor Dysfunction in Patients With Functional Gastroduodenal Symptoms. American Journal of Gastroenterology, 2017, 112, 1689-1699.	0.4	67
249	Relamorelin for the treatment of gastrointestinal motility disorders. Expert Opinion on Investigational Drugs, 2017, 26, 1189-1197.	4.1	22
250	Performance characteristics of serum C4 and FGF19 measurements to exclude the diagnosis of bile acid diarrhoea in IBS-related diarrhoea and functional diarrhoea. Alimentary Pharmacology and Therapeutics, 2017, 46, 581-588.	3.7	58
251	Relationship between Gastric Emptying or Gastric Accommodation and Postprandial Symptoms Observed After Ingestion of a Maximum Volume of a Nutrient Drink in 285 Participants. Gastroenterology, 2017, 152, S932-S933.	1.3	1
252	Relamorelin in Patients with Diabetic Gastroparesis: Efficacy and Safety Results from a Phase 2B Randomized, Double-Blind, Placebo-Controlled, 12-Week Study (RM-131-009). Gastroenterology, 2017, 152, S139-S140.	1.3	7

#	ARTICLE	IF	CITATIONS
253	Effects of Liraglutide on Gastric Emptying, Gastric Accommodation, Satiety and Satiety after 16 Weeks' Treatment: A Single-Center, Randomized, Placebo-Controlled Trial in 32 Patients. <i>Gastroenterology</i> , 2017, 152, S633-S634.	1.3	1
254	Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study. <i>Gastroenterology</i> , 2017, 153, 1240-1250.e2.	1.3	125
255	Effects of NK1 receptors on gastric motor functions and satiety in healthy humans: results from a controlled trial with the NK1 antagonist aprepitant. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 313, G505-G510.	3.4	44
256	Relationship of gastric emptying or accommodation with satiety, satiety, and postprandial symptoms in health. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 313, G442-G447.	3.4	38
257	Chronic constipation. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17095.	30.5	203
258	Breath Testing Consensus Guidelines for SIBO: RES IPSA LOCQUITUR. <i>American Journal of Gastroenterology</i> , 2017, 112, 1888-1889.	0.4	7
259	Modulating bile acid pathways and TGR5 receptors for treating liver and GI diseases. <i>Current Opinion in Pharmacology</i> , 2017, 37, 80-86.	3.5	37
260	Pharmacogenetics and the treatment of functional gastrointestinal disorders. <i>Pharmacogenomics</i> , 2017, 18, 1085-1094.	1.3	5
261	Pathophysiology, Evaluation, and Management of Chronic Watery Diarrhea. <i>Gastroenterology</i> , 2017, 152, 515-532.e2.	1.3	102
262	Exploring hypotheses and rationale for causes of infantile colic. <i>Neurogastroenterology and Motility</i> , 2017, 29, e12943.	3.0	30
263	Gluten-induced symptoms in diarrhea-predominant irritable bowel syndrome are associated with increased myosin light chain kinase activity and claudin-15 expression. <i>Laboratory Investigation</i> , 2017, 97, 14-23.	3.7	43
264	Relationship Between Gastric Emptying and Diurnal Glycemic Control in Type 1 Diabetes Mellitus: A Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 398-406.	3.6	24
265	Colonic Transit and Bile Acid Synthesis or Excretion in Patients With Irritable Bowel Syndrome—Diarrhea Without Bile Acid Malabsorption. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 720-727.e1.	4.4	43
266	Presence of intraepithelial food antigen in patients with active eosinophilic oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 427-433.	3.7	30
267	Pharmacotherapy for Irritable Bowel Syndrome. <i>Journal of Clinical Medicine</i> , 2017, 6, 101.	2.4	33
268	The Management of Obesity. , 2017, , 47-57.		0
269	Regional Colonic Transit Pattern Does Not Conclusively Identify Evacuation Disorders in Constipated Patients with Delayed Colonic Transit. <i>Journal of Neurogastroenterology and Motility</i> , 2017, 23, 92-100.	2.4	8
270	Secretory diarrhea and hypokalemia associated with colonic pseudo-obstruction: A case study and systematic analysis of the literature. <i>Neurogastroenterology and Motility</i> , 2017, 29, e13120.	3.0	25



#	ARTICLE	IF	CITATIONS
271	A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Naloxegol on Gastric, Small Bowel, and Colonic Transit in Healthy Subjects Receiving Codeine or Placebo: 2017 Fellows-in-Training Award (Functional Bowel Disease Category) 2017 Presidential Poster Award. American Journal of Gastroenterology, 2017, 112, S230.	0.4	1
272	Role of Nutrition in Understanding Common Gastrointestinal Disorders. , 2017, , 129-138.		0
273	Future directions in functional gastrointestinal disorders “microbiota, faecal transplants and pharmaceutical approaches. , 2017, , 269-278.		0
274	Medical Therapies in the Pipeline for Irritable Bowel Syndrome. Gastroenterology and Hepatology, 2017, 13, 550-552.	0.1	2
275	Colon: anatomy and structural anomalies. , 2016, , 24-29.		0
276	Laparoscopy and Laparotomy. , 2016, , 698-701.		1
277	Tumors of the Biliary Tract. , 2016, , 368-373.		1
278	Capsule and Small Bowel Endoscopy. , 2016, , 621-625.		0
279	Tumors of the Stomach. , 2016, , 149-152.		0
280	Miscellaneous Diseases of the Stomach. , 2016, , 153-156.		1
281	Zollinger-Ellison Syndrome. , 2016, , 135-139.		1
282	Effects of ghrelin receptor agonist, relamorelin, on gastric motor functions and satiation in healthy volunteers. Neurogastroenterology and Motility, 2016, 28, 1705-1713.	3.0	42
283	Effects of hemin on heme oxygenase-1, gastric emptying, and symptoms in diabetic gastroparesis. Neurogastroenterology and Motility, 2016, 28, 1731-1740.	3.0	33
284	Drug-resin drug interactions in patients with delayed gastric emptying: What is optimal time window for drug administration?. Neurogastroenterology and Motility, 2016, 28, 1268-1271.	3.0	8
285	Prucalopride induces high-amplitude propagating contractions in the colon of patients with chronic constipation: a randomized study. Neurogastroenterology and Motility, 2016, 28, 1341-1348.	3.0	26
286	Chemical and molecular factors in irritable bowel syndrome: current knowledge, challenges, and unanswered questions. American Journal of Physiology - Renal Physiology, 2016, 311, G777-G784.	3.4	29
287	Pilot study of small bowel mucosal gene expression in patients with irritable bowel syndrome with diarrhea. American Journal of Physiology - Renal Physiology, 2016, 311, G365-G376.	3.4	25
288	Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches. Handbook of Experimental Pharmacology, 2016, 239, 75-113.	1.8	25

#	ARTICLE	IF	CITATIONS
289	Improving the detection of environmental enteric dysfunction: a lactulose, rhamnose assay of intestinal permeability in children aged under 5 years exposed to poor sanitation and hygiene. <i>BMJ Global Health</i> , 2016, 1, e000066.	4.7	56
290	Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2357-2372.	2.3	68
291	Effects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e173.	2.5	70
292	2015 James W. Freston Single Topic Conference: A Renaissance in the Understanding and Management of Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, e77-e86.	4.4	3
293	Tu1809 Small Intestinal Mucosal Expression of Candidate Pathobiological Mechanisms in IBS-Diarrhea (IBS-D) and Healthy Controls. <i>Gastroenterology</i> , 2016, 150, S954.	1.3	1
294	Measurement of Gastrointestinal and Colonic Motor Functions in Humans and Animals. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2016, 2, 412-428.	4.5	49
295	Pharmacologic, Pharmacokinetic, and Pharmacogenomic Aspects of Functional Gastrointestinal Disorders. <i>Gastroenterology</i> , 2016, 150, 1319-1331.e20.	1.3	26
296	Fundamentals of Neurogastroenterology: Physiology/Motility "Sensation. <i>Gastroenterology</i> , 2016, 150, 1292-1304.e2.	1.3	103
297	Relamorelin Reduces Vomiting Frequency and Severity and Accelerates Gastric Emptying in Adults With Diabetic Gastroparesis. <i>Gastroenterology</i> , 2016, 151, 87-96.e6.	1.3	112
298	2015 James W. Freston Single Topic Conference: "Renaissance" in the Understanding and Management of Irritable Bowel Syndrome. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2016, 2, 394-399.e2.	4.5	4
299	Oral Manifestation of Gastrointestinal Diseases. , 2016, , 574-581.		0
300	Rifaximin, Microbiota Biology, and Hepatic Encephalopathy. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e195.	2.5	5
301	Short bowel syndrome. , 2016, , 189-201.		0
302	Enhancing High Value Care in Gastroenterology Practice. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1376-1384.	4.4	8
303	Enhancing Diagnostic Performance of Symptom-Based Criteria for Irritable Bowel Syndrome by Additional History and Limited Diagnostic Evaluation. <i>American Journal of Gastroenterology</i> , 2016, 111, 1446-1454.	0.4	41
304	<sup>13</sup> C mannitol as a novel biomarker for measurement of intestinal permeability. <i>Neurogastroenterology and Motility</i> , 2016, 28, 1114-1119.	3.0	42
305	Cystic Lesions of the Pancreas. , 2016, , 324-328.		0
306	Chronic Hepatitis B Viral Infection. , 2016, , 387-391.		0

#	ARTICLE	IF	CITATIONS
307	Response to "Teduglutide and Intestinal Permeability in Short Bowel Syndrome" Journal of Parenteral and Enteral Nutrition, 2016, 40, 1087-1088.	2.6	0
308	Ulcerative Colitis: Clinical Manifestations and Management. , 2016, , 216-224.		1
309	Gastritis and Gastropathy. , 2016, , 140-148.		0
310	Hepatitis C Virus Infection. , 2016, , 392-396.		0
311	Management of Upper Gastrointestinal Hemorrhage Related to Portal Hypertension. , 2016, , 664-674.		0
312	Gastrointestinal Manifestations of Immunological Disorders. , 2016, , 509-514.		0
313	PTU-137...Enhanced Diagnostic Performance of Symptom-Based Criteria for Irritable Bowel Syndrome by History and Diagnostic Evaluation: Abstract PTU-137 Table 1. Gut, 2016, 65, A125.1-A125.	12.1	0
314	Functional Dyspepsia and Gastroparesis. Digestive Diseases, 2016, 34, 491-499.	1.9	67
315	High-Fat Diet, Dysbiosis, and Gastrointestinal and Colonic Transit: Is There a Missing Link?. Cellular and Molecular Gastroenterology and Hepatology, 2016, 2, 257-258.	4.5	3
316	964 Prevalence of Opioid Analgesic Use Among Patients Presenting to Emergency Department With Abdominal Pain That Is Investigated With Emergent Abdominal CT Scan. Gastroenterology, 2016, 150, S192-S193.	1.3	1
317	Tu1793 Effects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome: A Randomized, Double-Blinded Trial. Gastroenterology, 2016, 150, S948-S949.	1.3	4
318	Characteristics of chronic megacolon among patients diagnosed with multiple endocrine neoplasia type 2B. United European Gastroenterology Journal, 2016, 4, 449-454.	3.8	22
319	Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events. JAMA - Journal of the American Medical Association, 2016, 315, 2424.	7.4	614
320	Evaluating the safety and the effects on colonic compliance of neostigmine during motility testing in patients with chronic constipation. Neurogastroenterology and Motility, 2016, 28, 871-878.	3.0	11
321	Novel Diet, Drugs, and Gastric Interventions for Gastroparesis. Clinical Gastroenterology and Hepatology, 2016, 14, 1072-1080.	4.4	66
322	Opioid-induced constipation: advances and clinical guidance. Therapeutic Advances in Chronic Disease, 2016, 7, 121-134.	2.5	79
323	Editorial: Dissecting Molecular Mechanisms in Bile Acid Diarrhea. American Journal of Gastroenterology, 2016, 111, 433-435.	0.4	7
324	Gastrointestinal traits: individualizing therapy for obesity with drugs and devices. Gastrointestinal Endoscopy, 2016, 83, 48-56.	1.0	26

#	ARTICLE	IF	CITATIONS
325	Biomarkers for bile acid diarrhoea in functional bowel disorder with diarrhoea: a systematic review and meta-analysis. <i>Gut</i> , 2016, 65, 1951-1959.	12.1	101
326	Short-Term Effects of Relamorelin on Descending Colon Motility in Chronic Constipation: A Randomized, Controlled Trial. <i>Digestive Diseases and Sciences</i> , 2016, 61, 852-860.	2.3	27
327	Acute Effects of a Glucagon-Like Peptide 2 Analogue, Teduglutide, on Gastrointestinal Motor Function and Permeability in Adult Patients With Short Bowel Syndrome on Home Parenteral Nutrition. <i>Journal of Parenteral and Enteral Nutrition</i> , 2016, 40, 1089-1095.	2.6	27
328	Association of <i>UCP3</i> rs1626521 with obesity and stomach functions in humans. <i>Obesity</i> , 2015, 23, 898-906.	3.0	6
329	Editorial: colesevelam effects on faecal bile acids in <i>IBS</i> with diarrhoea – author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 697-697.	3.7	0
330	Ehlers Danlos syndrome and gastrointestinal manifestations: a 20-year experience at Mayo Clinic. <i>Neurogastroenterology and Motility</i> , 2015, 27, 1657-1666.	3.0	144
331	Review article: biomarkers and personalised therapy in functional lower gastrointestinal disorders. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 818-828.	3.7	39
332	Translation of disease associated gene signatures across tissues. <i>International Journal of Data Mining and Bioinformatics</i> , 2015, 11, 301.	0.1	4
333	Effect of neostigmine on gastroduodenal motility in patients with suspected gastrointestinal motility disorders. <i>Neurogastroenterology and Motility</i> , 2015, 27, 1736-1746.	3.0	38
334	Regional gastrointestinal transit and <i>pH</i> studied in 215 healthy volunteers using the wireless motility capsule: influence of age, gender, study country and testing protocol. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 761-772.	3.7	117
335	Imaging approach to measuring small bowel motility. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 309, G411-G412.	3.4	1
336	A Pilot Study of the Effect of Daikenchuto on Rectal Sensation in Patients with Irritable Bowel Syndrome. <i>Journal of Neurogastroenterology and Motility</i> , 2015, 22, 69-77.	2.4	7
337	Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study. <i>Physiological Reports</i> , 2015, 3, e12610.	1.7	45
338	Bile Acid Diarrhea: Prevalence, Pathogenesis, and Therapy. <i>Gut and Liver</i> , 2015, 9, 332-9.	2.9	171
339	Definitions and Outcome Measures of Clinical Trials Regarding Opioid-induced Constipation. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 9-16.	2.2	71
340	Chronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunities. <i>Therapeutic Advances in Gastroenterology</i> , 2015, 8, 206-220.	3.2	73
341	Comparison of adequate relief with symptom, global, and responder endpoints in linaclotide phase 3 trials in <i>IBS-C</i> . <i>United European Gastroenterology Journal</i> , 2015, 3, 53-62.	3.8	11
342	Consensus Recommendations on Initiating Prescription Therapies for Opioid-Induced Constipation. <i>Pain Medicine</i> , 2015, 16, 2324-2337.	1.9	95

#	ARTICLE	IF	CITATIONS
343	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2383.	4.4	0
344	Prokinetics in Gastroparesis. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 97-111.	2.2	89
345	Intestinal Secretory Mechanisms in Irritable Bowel Syndrome—Diarrhea. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1051-1057.	4.4	34
346	American college of gastroenterology monograph on the management of irritable bowel syndrome. Expert Opinion on Pharmacotherapy, 2015, 16, 629-632.	1.8	8
347	Guanylate Cyclase C Agonists: Emerging Gastrointestinal Therapies and Actions. <i>Gastroenterology</i> , 2015, 148, 483-487.	1.3	36
348	Colonic mucosal gene expression and genotype in irritable bowel syndrome patients with normal or elevated fecal bile acid excretion. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 309, G10-G20.	3.4	39
349	Endoscopic Mucosal Impedance Measurements Correlate With Eosinophilia and Dilation of Intercellular Spaces in Patients With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1242-1248.e1.	4.4	126
350	Early investigational therapeutics for gastrointestinal motility disorders: from animal studies to Phase II trials. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 769-779.	4.1	23
351	Pharmacogenetics in irritable bowel syndrome. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1187-1191.	3.3	5
352	Effect of Amitriptyline and Escitalopram on Functional Dyspepsia: A Multicenter, Randomized Controlled Study. <i>Gastroenterology</i> , 2015, 149, 340-349.e2.	1.3	262
353	A Randomized Trial of 5-Hydroxytryptamine <sub>4</sub> Receptor Agonist, YKP10811, on Colonic Transit and Bowel Function in Functional Constipation. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 701-708.e1.	4.4	25
354	Clinical Features and Colonic Motor Disturbances in Chronic Megacolon in Adults. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2398-2407.	2.3	29
355	Quantitative Gastrointestinal and Psychological Traits Associated With Obesity and Response to Weight-Loss Therapy. <i>Gastroenterology</i> , 2015, 148, 537-546.e4.	1.3	143
356	Six and 12 Weeks of Caloric Restriction Increases $\beta$ Cell Function and Lowers Fasting and Postprandial Glucose Concentrations in People with Type 2 Diabetes. <i>Journal of Nutrition</i> , 2015, 145, 2046-2051.	2.9	40
357	Effect of colesvelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 438-448.	3.7	91
358	Emerging treatments in Neurogastroenterology: relamorelin: a novel gastrocolokinetic synthetic ghrelin agonist. <i>Neurogastroenterology and Motility</i> , 2015, 27, 324-332.	3.0	48
359	Association between health-related quality of life and symptoms in patients with chronic constipation: an integrated analysis of three phase 3 trials of prucalopride. <i>Neurogastroenterology and Motility</i> , 2015, 27, 397-405.	3.0	42
360	A meta-analysis of immunogenetic Case-Control Association Studies in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2015, 27, 717-727.	3.0	35

#	ARTICLE	IF	CITATIONS
361	Therapeutic targeting of bile acids. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 309, G209-G215.	3.4	63
362	Specific inhibition of bile acid transport alters plasma lipids and GLP-1. <i>BMC Cardiovascular Disorders</i> , 2015, 15, 75.	1.7	49
363	Relamorelin Relieves Constipation and Accelerates Colonic Transit in a Phase 2, Placebo-Controlled, Randomized Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2312-2319.e1.	4.4	39
364	New and Investigational Agents for Irritable Bowel Syndrome. <i>Current Gastroenterology Reports</i> , 2015, 17, 46.	2.5	8
365	The stomach in health and disease. <i>Gut</i> , 2015, 64, 1650-1668.	12.1	283
366	Accuracy, Safety, and Tolerability of Tissue Collection by Cytosponge vs Endoscopy for Evaluation of Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 77-83.e2.	4.4	132
367	Small intestinal permeability in patients with eosinophilic oesophagitis during active phase and remission. <i>Gut</i> , 2015, 64, 538-543.	12.1	14
368	Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts. <i>Gut</i> , 2015, 64, 1774-1782.	12.1	97
369	Relationship Between Glycemic Control and Gastric Emptying in Poorly Controlled Type 2 Diabetes. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 466-476.e1.	4.4	75
370	Peripheral Mechanisms in Appetite Regulation. <i>Gastroenterology</i> , 2015, 148, 1219-1233.	1.3	163
371	Disturbances of Gastrointestinal Motility and the Nervous System. , 2014, , 255-271.		2
372	The effect of vagal nerve blockade using electrical impulses on glucose metabolism in nondiabetic subjects. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2014, 7, 305.	2.4	9
373	Increased Nutrient Sensitivity and Plasma Concentrations of Enteral Hormones During Duodenal Nutrient Infusion in Functional Dyspepsia. <i>American Journal of Gastroenterology</i> , 2014, 109, 1910-1920.	0.4	31
374	Prevalence of colonic motor or evacuation disorders in patients presenting with chronic nausea and vomiting evaluated by a single gastroenterologist in a tertiary referral practice. <i>Neurogastroenterology and Motility</i> , 2014, 26, 131-138.	3.0	41
375	Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or) <i>Tj ETQq1 1 0,784314 rgBT /Ov</i>	3.7	126
376	Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. <i>Neurogastroenterology and Motility</i> , 2014, 26, 1386-1395.	3.0	171
377	Advances in understanding of bile acid diarrhea. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 49-61.	3.0	79
378	Gastrointestinal morbidity in obesity. <i>Annals of the New York Academy of Sciences</i> , 2014, 1311, 42-56.	3.8	31

#	ARTICLE	IF	CITATIONS
379	Novel association of rectal evacuation disorder and rumination syndrome: Diagnosis, comorbidities, and treatment. United European Gastroenterology Journal, 2014, 2, 38-46.	3.8	32
380	Recent advances in clinical practice challenges and opportunities in the management of obesity. Gut, 2014, 63, 687-695.	12.1	82
381	RNA sequencing shows transcriptomic changes in rectosigmoid mucosa in patients with irritable bowel syndrome-diarrhea: a pilot case-control study. American Journal of Physiology - Renal Physiology, 2014, 306, G1089-G1098.	3.4	52
382	Tu1798 Characterization of Hypothalamic Hunger and Satiety Signals With Pulsed Arterial Spin Labeling MRI. Gastroenterology, 2014, 146, S-845.	1.3	1
383	Loss-of-Function of the Voltage-Gated Sodium Channel NaV1.5 (Channelopathies) in Patients With Irritable Bowel Syndrome. Gastroenterology, 2014, 146, 1659-1668.	1.3	120
384	Tu2037 Effects of YKP10811, a Selective 5-HT4 Receptor Agonist, in Patients with Functional Constipation: A Randomized, Controlled, Phase II Study. Gastroenterology, 2014, 146, S-902-S-903.	1.3	1
385	Effects of Topical Steroids on Tight Junction Proteins and Spongiosis in Esophageal Epithelia of Patients With Eosinophilic Esophagitis. Clinical Gastroenterology and Hepatology, 2014, 12, 1824-1829.e1.	4.4	83
386	676 Validating a Biomarker for Irritable Bowel Syndrome. Gastroenterology, 2014, 146, S-119-S-120.	1.3	1
387	<i>On the fiftieth anniversary</i> Postinfectious irritable bowel syndrome: mechanisms related to pathogens. Neurogastroenterology and Motility, 2014, 26, 156-167.	3.0	43
388	Contribution of Endogenous Glucagon-Like Peptide 1 to Glucose Metabolism After Roux-en-Y Gastric Bypass. Diabetes, 2014, 63, 483-493.	0.6	123
389	Association of melanocortin 4 receptor gene variation with satiation and gastric emptying in overweight and obese adults. Genes and Nutrition, 2014, 9, 384.	2.5	16
390	Pilot trial: Pregabalin on colonic sensorimotor functions in irritable bowel syndrome. Digestive and Liver Disease, 2014, 46, 113-118.	0.9	4
391	Physiological underpinnings of irritable bowel syndrome: neurohormonal mechanisms. Journal of Physiology, 2014, 592, 2967-2980.	2.9	77
392	Validating biomarkers of treatable mechanisms in irritable bowel syndrome. Neurogastroenterology and Motility, 2014, 26, 1677-1685.	3.0	46
393	Effect of Increased Bile Acid Synthesis or Fecal Excretion in Irritable Bowel Syndrome-Diarrhea. American Journal of Gastroenterology, 2014, 109, 1621-1630.	0.4	82
394	Genetic variation in GPBAR1 predisposes to quantitative changes in colonic transit and bile acid excretion. American Journal of Physiology - Renal Physiology, 2014, 307, G508-G516.	3.4	45
395	Novel therapeutic agents in neurogastroenterology: advances in the past year. Neurogastroenterology and Motility, 2014, 26, 1070-1078.	3.0	16
396	Irritable bowel syndrome-diarrhea: characterization of genotype by exome sequencing, and phenotypes of bile acid synthesis and colonic transit. American Journal of Physiology - Renal Physiology, 2014, 306, G13-G26.	3.4	30

#	ARTICLE	IF	CITATIONS
397	Effects of Clonidine in Women With Fecal Incontinence. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 843-851.e2.	4.4	43
398	Ramosetron in Irritable Bowel Syndrome With Diarrhea: New Hope or the Same Old Story?. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 960-962.	4.4	11
399	64 RNA Sequencing Shows Transcriptomic Changes in Rectosigmoid Mucosa in Patients With Irritable Bowel Syndrome-Diarrhea. <i>Gastroenterology</i> , 2014, 146, S-18.	1.3	1
400	Mo1289 Comparing Gastroparesis Symptom Severity Between Patients With Idiopathic and Diabetic Gastroparesis: The Gcsi-Dd Reliably Assesses Symptoms From Both Diabetic and Idiopathic Gastroparesis. <i>Gastroenterology</i> , 2014, 146, S-609.	1.3	1
401	929a A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-131 in Patients with Diabetic Gastroparesis. <i>Gastroenterology</i> , 2014, 146, S-158-S-159.	1.3	21
402	Sa2051 A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Parallel-Group Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of RM-131 in Patients With Chronic Constipation. <i>Gastroenterology</i> , 2014, 146, S-364.	1.3	7
403	Re: Halmos etÂAal, A Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2014, 146, 1829-1830.	1.3	15
404	Proximal Megacolon in an Adult. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, e83-e84.	4.4	3
405	Elobixibat and its potential role in chronic idiopathic constipation. <i>Therapeutic Advances in Gastroenterology</i> , 2014, 7, 167-175.	3.2	72
406	Evaluation of Alosetron Using the New FDA Composite Endpoint Demonstrates Strong Treatment Effect in Females With Severe Irritable Bowel Syndrome With Diarrhea. <i>American Journal of Gastroenterology</i> , 2014, 109, S535.	0.4	4
407	Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1151-1160.	1.8	48
408	Effects on gastrointestinal functions and symptoms of serotonergic psychoactive agents used in functional gastrointestinal diseases. <i>Journal of Gastroenterology</i> , 2013, 48, 177-181.	5.1	50
409	Novel and Validated Approaches for Gastric Emptying Scintigraphy in Patients with Suspected Gastroparesis. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1813-1815.	2.3	39
410	A randomised controlled study of the effect of cholinesterase inhibition on colon function in patients with diabetes mellitus and constipation. <i>Gut</i> , 2013, 62, 708-715.	12.1	76
411	A ghrelin agonist fails to show benefit in patients with diabetic gastroparesis: let's not throw the baby out with the bath water. <i>Neurogastroenterology and Motility</i> , 2013, 25, 859-863.	3.0	18
412	Ghrelin and motilin receptor agonists: a long and winding misconception. <i>Neurogastroenterology and Motility</i> , 2013, 25, 1003-1003.	3.0	0
413	Clinical Guideline: Management of Gastroparesis. <i>American Journal of Gastroenterology</i> , 2013, 108, 18-37.	0.4	904
414	Methods for Diagnosis of Bile Acid Malabsorption in Clinical Practice. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1232-1239.	4.4	106



#	ARTICLE	IF	CITATIONS
415	Elobixibat for the treatment of constipation. Expert Opinion on Investigational Drugs, 2013, 22, 277-284.	4.1	32
416	The Ghrelin Agonist RM-131 Accelerates Gastric Emptying of Solids and Reduces Symptoms in Patients With Type 1 Diabetes Mellitus. Clinical Gastroenterology and Hepatology, 2013, 11, 1453-1459.e4.	4.4	97
417	Reply. Gastroenterology, 2013, 145, 694.	1.3	0
418	Gastric Antral Injections of Botulinum Toxin Delay Gastric Emptying but Do Not Reduce Body Weight. Clinical Gastroenterology and Hepatology, 2013, 11, 145-150.e1.	4.4	33
419	925g Plecanatide, a Novel Guanylate Cyclase-C (GC-C) Receptor Agonist, is Efficacious and Safe in Patients with Chronic Idiopathic Constipation (CIC): Results from a 951 Patient, 12 Week, Multi-Center Trial. Gastroenterology, 2013, 144, S-163.	1.3	26
420	Bowel Functions, Fecal Unconjugated Primary and Secondary Bile Acids, and Colonic Transit in Patients With Irritable Bowel Syndrome. Clinical Gastroenterology and Hepatology, 2013, 11, 1270-1275.e1.	4.4	132
421	Comprehensive assessment of gastric emptying with a stable isotope breath test. Neurogastroenterology and Motility, 2013, 25, e60-9.	3.0	55
422	Current management strategies and emerging treatments for functional dyspepsia. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 187-194.	17.8	155
423	A Controlled Trial of Gluten-Free Diet in Patients With Irritable Bowel Syndrome-Diarrhea: Effects on Bowel Frequency and Intestinal Function. Gastroenterology, 2013, 144, 903-911.e3.	1.3	386
424	Efficacy and safety of oral prucalopride in women with chronic constipation in whom laxatives have failed: an integrated analysis. United European Gastroenterology Journal, 2013, 1, 48-59.	3.8	42
425	Cannabinoid receptor 1 gene and irritable bowel syndrome: phenotype and quantitative traits. American Journal of Physiology - Renal Physiology, 2013, 304, G553-G560.	3.4	49
426	The SNMMI and EANM Practice Guideline for Small-Bowel and Colon Transit 1.0. Journal of Nuclear Medicine, 2013, 54, 2004-2013.	5.0	50
427	Simplifying the measurement of gastric accommodation using <sup>13</sup> C-spect. Neurogastroenterology and Motility, 2013, 25, 542-546.	3.0	9
428	Genetics of human gastrointestinal sensation. Neurogastroenterology and Motility, 2013, 25, 458-466.	3.0	32
429	Interpretation of overall colonic transit in defecation disorders in males and females. Neurogastroenterology and Motility, 2013, 25, 502.	3.0	18
430	Commentary: fibroblast growth factor 19 in patients with bile acid diarrhoea. Alimentary Pharmacology and Therapeutics, 2013, 38, 1320-1321.	3.7	1
431	Randomised clinical trial: the effects of d-aikenchuto, TU€100, on gastrointestinal and colonic transit, anorectal and bowel function in female patients with functional constipation. Alimentary Pharmacology and Therapeutics, 2013, 37, 776-785.	3.7	35
432	Response to Arnold and Beaves. American Journal of Gastroenterology, 2013, 108, 1539-1540.	0.4	1

#	ARTICLE	IF	CITATIONS
433	Diagnostic Assessment of Diabetic Gastroparesis. <i>Diabetes</i> , 2013, 62, 2667-2673.	0.6	60
434	Peripheral Mechanisms in Irritable Bowel Syndrome. <i>New England Journal of Medicine</i> , 2013, 368, 577-579.	27.0	144
435	Randomized Controlled Phase Ib Study of Ghrelin Agonist, RM-131, in Type 2 Diabetic Women With Delayed Gastric Emptying. <i>Diabetes Care</i> , 2013, 36, 41-48.	8.6	93
436	Pharmacological agents currently in clinical trials for disorders in neurogastroenterology. <i>Journal of Clinical Investigation</i> , 2013, 123, 4111-4120.	8.2	27
437	Physiology of the Colon and Its Measurement. , 2013, , 1728-1739.		0
438	Treatment with Methylnaltrexone and IVIG for Paraneoplastic Gastrointestinal Dysmotility. <i>Gastroenterology and Hepatology</i> , 2013, 9, 51-3.	0.1	2
439	Regional colon transit in patients with dys-synergic defaecation or slow transit in patients with constipation. <i>Gut</i> , 2012, 61, 1132-1139.	12.1	88
440	Irritable Bowel Syndrome: Methods, Mechanisms, and Pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 302, G1075-G1084.	3.4	97
441	Association of HLA-DQ gene with bowel transit, barrier function, and inflammation in irritable bowel syndrome with diarrhea. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 303, G1262-G1269.	3.4	56
442	Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 303, G120-G128.	3.4	38
443	Irritable bowel syndrome: how useful is the term and the "diagnosis"? <i>Therapeutic Advances in Gastroenterology</i> , 2012, 5, 381-386.	3.2	9
444	Editorial: Fecal Granins in IBS: Cause or Indicator of Intestinal or Colonic Irritation?. <i>American Journal of Gastroenterology</i> , 2012, 107, 448-450.	0.4	10
445	Governance of Clinical Research. <i>American Journal of Gastroenterology</i> , 2012, 107, 336-338.	0.4	4
446	Brain-Gut Axis. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2012, 54, 446-453.	1.8	64
447	Evolving Molecular Targets in the Treatment of Nonmalignant Gastrointestinal Diseases. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 306-320.	4.7	8
448	Methods for the Assessment of Small-Bowel and Colonic Transit. <i>Seminars in Nuclear Medicine</i> , 2012, 42, 113-123.	4.6	84
449	Letter: effects of oxycodone and tapentadol dosage on gastrointestinal function " author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 689-689.	3.7	0
450	Irritable Bowel Syndrome: Methods, Mechanisms, and Pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 303, G775-G785.	3.4	299

#	ARTICLE	IF	CITATIONS
451	Increased Bile Acid Biosynthesis Is Associated With Irritable Bowel Syndrome With Diarrhea. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1009-1015.e3.	4.4	178
452	Clarifications about linaclotide. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 15-15.	3.0	1
453	Guanylate cyclase C signaling: an intestinal secretory pathway where bugs, genes and new drugs intersect. <i>Genome Medicine</i> , 2012, 4, 50.	8.2	2
454	The role of pharmacogenetics in nonmalignant gastrointestinal diseases. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2012, 9, 173-184.	17.8	12
455	Peripheral Mechanisms in Irritable Bowel Syndrome. <i>New England Journal of Medicine</i> , 2012, 367, 1626-1635.	27.0	266
456	Tu1460 Randomized, Placebo-Controlled, Single-Dose, Crossover Study of the Effects of RM-131 in Type 2 Diabetics With Documented Delayed Gastric Emptying. <i>Gastroenterology</i> , 2012, 142, S-839.	1.3	4
457	Pharmacodynamic and Clinical Endpoints for Functional Colonic Disorders: Statistical Considerations. <i>Digestive Diseases and Sciences</i> , 2012, 58, 509-18.	2.3	21
458	Pharmacology of the New Treatments for Lower Gastrointestinal Motility Disorders and Irritable Bowel Syndrome. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 44-59.	4.7	42
459	Disorders of Gastrointestinal Motility. , 2012, , 862-868.		2
460	Pharmacogenetics of the Effects of Colesevelam on Colonic Transit in Irritable Bowel Syndrome with Diarrhea. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1222-1226.	2.3	30
461	Systematic review: cardiovascular safety profile of 5-HT <sub>4</sub> agonists developed for gastrointestinal disorders. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 745-767.	3.7	236
462	A randomised, placebo-controlled trial comparing the effects of tapentadol and oxycodone on gastrointestinal and colonic transit in healthy humans. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1088-1096.	3.7	52
463	Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome with diarrhea. <i>Neurogastroenterology and Motility</i> , 2012, 24, 358.	3.0	71
464	Evaluating symptom outcomes in gastroparesis clinical trials: validity and responsiveness of the Gastroparesis Cardinal Symptom Index Daily Diary (GCSI-DD). <i>Neurogastroenterology and Motility</i> , 2012, 24, 456-463.	3.0	101
465	Sensations of gas and pain and their relationship with compliance during distension in human colon. <i>Neurogastroenterology and Motility</i> , 2012, 24, 646.	3.0	4
466	Intestinal barrier function in health and gastrointestinal disease. <i>Neurogastroenterology and Motility</i> , 2012, 24, 503-512.	3.0	613
467	What are the important subsets of gastroparesis?. <i>Neurogastroenterology and Motility</i> , 2012, 24, 597-603.	3.0	28
468	Performance characteristics of scintigraphic measurement of gastric emptying of solids in healthy participants. <i>Neurogastroenterology and Motility</i> , 2012, 24, 1076.	3.0	133

#	ARTICLE	IF	CITATIONS
469	Comparison of calculations to estimate gastric emptying half-time of solids in humans. <i>Neurogastroenterology and Motility</i> , 2012, 24, 1142-1145.	3.0	15
470	Enteroendocrine and Neuronal Mechanisms in Pathophysiology of Acute Infectious Diarrhea. <i>Digestive Diseases and Sciences</i> , 2012, 57, 19-27.	2.3	28
471	Epidemiology, Mechanisms, and Management of Diabetic Gastroparesis. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 5-12.	4.4	238
472	Comparison of Small Bowel and Colonic Mucosal Permeability in Ulcerative/Microscopic Colitis, Irritable Bowel Syndrome-Diarrhea, and Healthy Controls by Urinary Saccharide Excretion Measurements. <i>Gastroenterology</i> , 2011, 140, S-707-S-708.	1.3	4
473	Pharmacogenetic Trial of a Cannabinoid Agonist Shows Reduced Fasting Colonic Motility in Patients With Nonconstipated Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2011, 141, 1638-1647.e7.	1.3	84
474	Genetic Susceptibility to Inflammation is Associated With Colonic Transit and Other Intermediate Phenotypes in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2011, 140, S-152.	1.3	2
475	A Klotho <sup>Δ2</sup> Variant Mediates Protein Stability and Associates With Colon Transit in Irritable Bowel Syndrome With Diarrhea. <i>Gastroenterology</i> , 2011, 140, 1934-1942.	1.3	81
476	Opioid-Induced Constipation: Challenges and Therapeutic Opportunities. <i>American Journal of Gastroenterology</i> , 2011, 106, 835-842.	0.4	216
477	Association of TNFSF15 polymorphism with irritable bowel syndrome. <i>Gut</i> , 2011, 60, 1671-1677.	12.1	109
478	New Treatment Options for Chronic Constipation: Mechanisms, Efficacy and Safety. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2011, 25, 29B-35B.	1.7	10
479	HLA-DQ genotype is associated with accelerated small bowel transit in patients with diarrhea-predominant irritable bowel syndrome. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 481-487.	1.6	17
480	Effect of the $\alpha 2\delta$ ligand, pregabalin, on colonic sensory and motor functions in healthy adults. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 301, G377-G384.	3.4	14
481	Performance characteristics of the measurement of gastric volume using single photon emission computed tomography. <i>Neurogastroenterology and Motility</i> , 2011, 23, 308-315.	3.0	47
482	Association of genetic variation in cannabinoid mechanisms and gastric motor functions and satiation in overweight and obesity. <i>Neurogastroenterology and Motility</i> , 2011, 23, 637-e257.	3.0	13
483	Genetic susceptibility to inflammation and colonic transit in lower functional gastrointestinal disorders: preliminary analysis. <i>Neurogastroenterology and Motility</i> , 2011, 23, 935.	3.0	40
484	Association of bile acid receptor TGR5 variation and transit in health and lower functional gastrointestinal disorders. <i>Neurogastroenterology and Motility</i> , 2011, 23, 995-e458.	3.0	44
485	Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies. <i>Neurogastroenterology and Motility</i> , 2011, 23, 8-23.	3.0	305
486	LX-1031, a tryptophan 5-hydroxylase inhibitor, and its potential in chronic diarrhea associated with increased serotonin. <i>Neurogastroenterology and Motility</i> , 2011, 23, 193-200.	3.0	41

#	ARTICLE	IF	CITATIONS
487	Association of <i>TCF7L2</i> Allelic Variations with Gastric Function, Satiation, and GLP-1 Levels. <i>Clinical and Translational Science</i> , 2011, 4, 183-187.	3.1	19
488	Proximal and Overall Gastric Emptying of Solids in Patients with Reduced Gastric Volume Accommodation Compared to Matched Controls. <i>Digestive Diseases and Sciences</i> , 2011, 56, 1729-1734.	2.3	12
489	Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation. <i>Expert Review of Gastroenterology and Hepatology</i> , 2011, 5, 301-310.	3.0	26
490	Inclusion criteria for pharmacodynamic and clinical trials in chronic idiopathic constipation: pitfalls in using Rome III for functional constipation. <i>Therapeutic Advances in Gastroenterology</i> , 2011, 4, 159-163.	3.2	11
491	Managing symptoms of irritable bowel syndrome in patients with inflammatory bowel disease. <i>Gut</i> , 2011, 60, 425-428.	12.1	20
492	Response to Sandner-Kiesling. <i>American Journal of Gastroenterology</i> , 2011, 106, 2200-2201.	0.4	0
493	Lubiprostone for the treatment of opioid-induced bowel dysfunction. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 983-990.	1.8	18
494	A Randomized Placebo-Controlled Phase IIb Trial of A3309, A Bile Acid Transporter Inhibitor, for Chronic Idiopathic Constipation. <i>American Journal of Gastroenterology</i> , 2011, 106, 1803-1812.	0.4	156
495	Effects of A3309, an Ileal Bile Acid Transporter Inhibitor, on Colonic Transit and Symptoms in Females With Functional Constipation. <i>American Journal of Gastroenterology</i> , 2011, 106, 2154-2164.	0.4	116
496	Validation of a Bowel Function Diary for Assessing Opioid-Induced Constipation. <i>American Journal of Gastroenterology</i> , 2011, 106, 497-506.	0.4	23
497	Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 301, G919-G928.	3.4	101
498	New Treatment Options for Chronic Constipation: Mechanisms, Efficacy and Safety. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2011, 25, 29B-35B.	1.7	4
499	New treatment options for chronic constipation: mechanisms, efficacy and safety. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2011, 25 Suppl B, 29B-35B.	1.7	4
500	Understanding measurements of intestinal permeability in healthy humans with urine lactulose and mannitol excretion. <i>Neurogastroenterology and Motility</i> , 2010, 22, e15-26.	3.0	96
501	Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. <i>Neurogastroenterology and Motility</i> , 2010, 22, 42.	3.0	93
502	Perspective: Conflict of Interest and Professional Organizations: Considerations and Recommendations. <i>Academic Medicine</i> , 2010, 85, 85-91.	1.6	28
503	OC-069...Efficacy of 12-week treatment with prucalopride (resolor) in patients with chronic constipation: combined results of three randomised, double-blind, placebo-controlled phase 3 trials. <i>Gut</i> , 2010, 59, A28.3-A29.	12.1	0
504	Emerging Pharmacologic Therapies for Irritable Bowel Syndrome. <i>Current Gastroenterology Reports</i> , 2010, 12, 408-416.	2.5	21

#	ARTICLE	IF	CITATIONS
505	Reproducibility and Performance Characteristics of Colonic Compliance, Tone, and Sensory Tests in Healthy Humans. <i>Digestive Diseases and Sciences</i> , 2010, 55, 709-715.	2.3	19
506	Effect of Meal Ingestion on Ileocolonic and Colonic Transit in Health and Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2010, 55, 384-391.	2.3	54
507	Review article: new receptor targets for medical therapy in irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 35-46.	3.7	49
508	Review article: metoclopramide and tardive dyskinesia. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 11-19.	3.7	270
509	The effects of methylnaltrexone alone and in combination with acutely administered codeine on gastrointestinal and colonic transit in health. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 884-893.	3.7	36
510	Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation – follow-up of patients from the pivotal studies. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1113-1123.	3.7	80
511	Gastroparesis and functional dyspepsia: excerpts from the AGA/ANMS meeting. <i>Neurogastroenterology and Motility</i> , 2010, 22, 113-133.	3.0	171
512	Performance characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and relationship to bowel functions. <i>Neurogastroenterology and Motility</i> , 2010, 22, 415-e95.	3.0	93
513	Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. <i>Neurogastroenterology and Motility</i> , 2010, 22, 293-e82.	3.0	120
514	Wireless pH-motility capsule for colonic transit: prospective comparison with radiopaque markers in chronic constipation. <i>Neurogastroenterology and Motility</i> , 2010, 22, 874.	3.0	185
515	A Preliminary Candidate Genotype-Intermediate Phenotype Study of Satiety and Gastric Motor Function in Obesity. <i>Obesity</i> , 2010, 18, 1201-1211.	3.0	15
516	Effect of Alginate on Satiety, Appetite, Gastric Function, and Selected Gut Satiety Hormones in Overweight and Obesity. <i>Obesity</i> , 2010, 18, 1579-1584.	3.0	67
517	Response to <i>Odunsi et al</i> . Results for CM3 Cannot Be Extrapolated to Alginates in General. <i>Obesity</i> , 2010, 18, 2070-2070.	3.0	0
518	Scintigraphic Biomarkers for Colonic Dysmotility. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 87, 748-753.	4.7	52
519	Effect of daikenchuto (TU-100) on gastrointestinal and colonic transit in humans. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 298, G970-G975.	3.4	111
520	Role of prucalopride, a serotonin (5-HT <sub>4</sub> ) receptor agonist, for the treatment of chronic constipation. <i>Clinical and Experimental Gastroenterology</i> , 2010, 3, 49.	2.3	40
521	Stomach Dysfunction in Diabetes Mellitus: Emerging Technology and Pharmacology. <i>Journal of Diabetes Science and Technology</i> , 2010, 4, 180-189.	2.2	13
522	Common Genetic Variation in <i>GLP1R</i> and Insulin Secretion in Response to Exogenous GLP-1 in Nondiabetic Subjects. <i>Diabetes Care</i> , 2010, 33, 2074-2076.	8.6	106

#	ARTICLE	IF	CITATIONS
523	Behavioural and new pharmacological treatments for constipation: getting the balance right. <i>Cut</i> , 2010, 59, 1288-1296.	12.1	42
524	Effects of Chenodeoxycholate and a Bile Acid Sequestrant, Colesevelam, on Intestinal Transit and Bowel Function. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 159-165.e5.	4.4	166
525	Do the Symptom-Based, Rome Criteria of Irritable Bowel Syndrome Lead to Better Diagnosis and Treatment Outcomes?. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 125.	4.4	11
526	Prucalopride for constipation. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 451-461.	1.8	28
527	Phenotypic Variation of Colonic Motor Functions in Chronic Constipation. <i>Gastroenterology</i> , 2010, 138, 89-97.	1.3	82
528	Neuropeptide S Receptor Induces Neuropeptide Expression and Associates With Intermediate Phenotypes of Functional Gastrointestinal Disorders. <i>Gastroenterology</i> , 2010, 138, 98-107.e4.	1.3	52
529	Dietary Fiber Supplements: Effects in Obesity and Metabolic Syndrome and Relationship to Gastrointestinal Functions. <i>Gastroenterology</i> , 2010, 138, 65-72.e2.	1.3	269
530	Chenodeoxycholate in Females With Irritable Bowel Syndrome-Constipation: A Pharmacodynamic and Pharmacogenetic Analysis. <i>Gastroenterology</i> , 2010, 139, 1549-1558.e1.	1.3	154
531	New-generation 5-HT <sub>4</sub> receptor agonists: potential for treatment of gastrointestinal motility disorders. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 765-775.	4.1	77
532	The Con Argument. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 129-132.	4.4	27
533	Current Medical Treatments of Dyspepsia and Irritable Bowel Syndrome. <i>Gastroenterology Clinics of North America</i> , 2010, 39, 481-493.	2.2	36
534	LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome. <i>IDrugs: the Investigational Drugs Journal</i> , 2010, 13, 921-8.	0.7	4
535	Mitochondrial DNA and gastrointestinal motor and sensory functions in health and functional gastrointestinal disorders. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 296, G510-G516.	3.4	44
536	Editorial: Is Adequate Relief Fatally Flawed or Adequate as an End Point in Irritable Bowel Syndrome?. <i>American Journal of Gastroenterology</i> , 2009, 104, 920-922.	0.4	12
537	Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 296, G295-G301.	3.4	61
538	Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome?. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 296, G1299-G1306.	3.4	106
539	Genetics and Irritable Bowel Syndrome: From Genomics to Intermediate Phenotype and Pharmacogenetics. <i>Digestive Diseases and Sciences</i> , 2009, 54, 2318-2324.	2.3	29
540	Apoptotic cell death of human interstitial cells of Cajal. <i>Neurogastroenterology and Motility</i> , 2009, 21, 85-93.	3.0	68

#	ARTICLE	IF	CITATIONS
541	Application of magnetic resonance imaging to measure fasting and postprandial volumes in humans. <i>Neurogastroenterology and Motility</i> , 2009, 21, 42-51.	3.0	66
542	Candidate genes and functional dyspepsia. <i>Neurogastroenterology and Motility</i> , 2009, 21, 94-94.	3.0	3
543	Optimizing analysis of stable isotope breath tests to estimate gastric emptying of solids. <i>Neurogastroenterology and Motility</i> , 2009, 21, 706.	3.0	45
544	Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. <i>Neurogastroenterology and Motility</i> , 2009, 21, 1256.	3.0	120
545	Development and content validity of a gastroparesis cardinal symptom index daily diary. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 670-680.	3.7	110
546	Effects of bisacodyl on ascending colon emptying and overall colonic transit in healthy volunteers. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 930-936.	3.7	79
547	Relationship between clinical features and gastric emptying disturbances in diabetes mellitus. <i>Clinical Endocrinology</i> , 2009, 70, 415-420.	2.4	131
548	Effect of age on the enteric nervous system of the human colon. <i>Neurogastroenterology and Motility</i> , 2009, 21, 746.	3.0	134
549	Pharmacogenetics of low dose clonidine in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2009, 21, 399-410.	3.0	25
550	Influence of clinical parameters on the results of <sup>13</sup> C-octanoic acid breath tests: examination of different mathematical models in a large patient cohort. <i>Neurogastroenterology and Motility</i> , 2009, 21, 1039.	3.0	40
551	Associations among binge eating behavior patterns and gastrointestinal symptoms: a population-based study. <i>International Journal of Obesity</i> , 2009, 33, 342-353.	3.4	66
552	Measurement of serum 7 $\alpha$ -hydroxy- $^4\beta$ -cholestan- $^3\alpha$ -one (or 7 $\alpha$ -C4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry. <i>Neurogastroenterology and Motility</i> , 2009, 21, 734.	3.0	135
553	Actions and therapeutic pathways of ghrelin for gastrointestinal disorders. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2009, 6, 343-352.	17.8	101
554	Peripheral mechanisms in the control of appetite and related experimental therapies in obesity. <i>Regulatory Peptides</i> , 2009, 156, 24-27.	1.9	19
555	Current and novel therapeutic options for irritable bowel syndrome management. <i>Digestive and Liver Disease</i> , 2009, 41, 854-862.	0.9	41
556	Cannabinoids in intestinal inflammation and cancer. <i>Pharmacological Research</i> , 2009, 60, 117-125.	7.1	93
557	160 Long-Term Follow-Up of Safety and Satisfaction with Bowel Function in Response to Oral Prucalopride in Patients with Chronic Constipation. <i>Gastroenterology</i> , 2009, 136, A-31.	1.3	3
558	Developing Irritable Bowel Syndrome Guidelines Through Meta-analyses: Does the Emperor Really Have New Clothes?. <i>Gastroenterology</i> , 2009, 137, 766-769.	1.3	23



#	ARTICLE	IF	CITATIONS
559	Psychometric Evaluation of Patient-Reported Outcomes in Irritable Bowel Syndrome Randomized Controlled Trials: A Rome Foundation Report. <i>Gastroenterology</i> , 2009, 137, 1944-1953.e3.	1.3	66
560	Selection of electrical algorithms to treat obesity with intermittent vagal block using an implantable medical device. <i>Surgery for Obesity and Related Diseases</i> , 2009, 5, 224-229.	1.2	52
561	Selected Interventions in Nuclear Medicine: Gastrointestinal Motor Functions. <i>Seminars in Nuclear Medicine</i> , 2009, 39, 186-194.	4.6	33
562	Gastric Emptying. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 823-827.	4.4	23
563	The Stomach in Diabetes: From Villain to Ally. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 285-287.	4.4	11
564	Serotonin in the gastrointestinal tract. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2009, 16, 53-59.	2.3	142
565	Feasibility and Application of 3-Dimensional Ultrasound for Measurement of Gastric Volumes in Healthy Adults and Adolescents. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2009, 48, 287-293.	1.8	31
566	Evolving Concepts of the Pathogenesis of Irritable Bowel Syndrome: To Treat the Brain or the Gut?. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2009, 48, S46-8.	1.8	21
567	Methods for measurement of gastric motility. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 296, G461-G475.	3.4	98
568	MOTILITY DISORDERS. , 2009, , 475-486.		0
569	Pilot study of pyridostigmine in constipated patients with autonomic neuropathy. <i>Clinical Autonomic Research</i> , 2008, 18, 194-202.	2.5	56
570	Asimadoline, a kappa-opioid agonist, and satiation in functional dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 1122-1131.	3.7	26
571	The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study. <i>Clinical Endocrinology</i> , 2008, 69, 737-744.	2.4	59
572	Comparison of mathematical methods for calculating colonic compliance in humans: power exponential, computer-based and manual linear interpolation models. <i>Neurogastroenterology and Motility</i> , 2008, 20, 330-335.	3.0	16
573	An exploratory study of the association of adrenergic and serotonergic genotype and gastrointestinal motor functions. <i>Neurogastroenterology and Motility</i> , 2008, 20, 213-219.	3.0	34
574	Enteric neurodegeneration in ageing. <i>Neurogastroenterology and Motility</i> , 2008, 20, 185-196.	3.0	60
575	Enteric neurodegeneration in ageing. <i>Neurogastroenterology and Motility</i> , 2008, 20, 417-417.	3.0	1
576	Relationship of cytochrome P450 pharmacogenetics to the effects of yohimbine on gastrointestinal transit and catecholamines in healthy subjects. <i>Neurogastroenterology and Motility</i> , 2008, 20, 891-899.	3.0	7

#	ARTICLE	IF	CITATIONS
577	Enteric neurodegeneration in ageing. <i>Neurogastroenterology and Motility</i> , 2008, 20, 418-429.	3.0	62
578	Novel pharmacology: asimadoline, a $\mu$ -opioid agonist, and visceral sensation. <i>Neurogastroenterology and Motility</i> , 2008, 20, 971-979.	3.0	63
579	American Neurogastroenterology and Motility Society consensus statement on intraluminal measurement of gastrointestinal and colonic motility in clinical practice. <i>Neurogastroenterology and Motility</i> , 2008, 20, 1269-1282.	3.0	217
580	Intra-abdominal vagal blocking (VBLOC therapy): Clinical results with a new implantable medical device. <i>Surgery</i> , 2008, 143, 723-731.	1.9	140
581	Pharmacogenomics in Gastrointestinal Disorders. <i>Methods in Molecular Biology</i> , 2008, 448, 395-412.	0.9	7
582	Clinical Challenges and Images in GI. <i>Gastroenterology</i> , 2008, 134, 1293-1635.	1.3	3
583	A Controlled Pharmacogenetic Trial of Sibutramine on Weight Loss and Body Composition in Obese or Overweight Adults. <i>Gastroenterology</i> , 2008, 135, 1142-1154.	1.3	43
584	Challenges to the Therapeutic Pipeline for Irritable Bowel Syndrome: End Points and Regulatory Hurdles. <i>Gastroenterology</i> , 2008, 135, 1877-1891.	1.3	65
585	Consensus Recommendations for Gastric Emptying Scintigraphy: A Joint Report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. <i>American Journal of Gastroenterology</i> , 2008, 103, 753-763.	0.4	588
586	Pharmacogenetics: potential role in the treatment of diabetes and obesity. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1109-1119.	1.8	14
587	Drug development and IBS drugs: experience from the past, current challenges, and proposal for the future. <i>Current Opinion in Pharmacology</i> , 2008, 8, 671-676.	3.5	5
588	W1310 Relationship Between Colonic Motor Functions and Transit in Constipation. <i>Gastroenterology</i> , 2008, 134, A-677.	1.3	1
589	Prospective Study of Motor, Sensory, Psychologic, and Autonomic Functions in Patients With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 772-781.e5.	4.4	212
590	T1405 Effects of a Novel Corticotrophin Releasing Factor Receptor-1 Antagonist, BMS-562086, On Gastrointestinal and Colonic Transit and Bowel Habits in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS). <i>Gastroenterology</i> , 2008, 134, A-548.	1.3	6
591	A Stable Isotope Breath Test With a Standard Meal for Abnormal Gastric Emptying of Solids in the Clinic and in Research. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 635-643.e1.	4.4	172
592	Alterations in Mucosal Immunity Identified in the Colon of Patients With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 194-205.	4.4	117
593	T1402 Efficacy of 12-Week Treatment with Prucalopride (Resolor <sup>®</sup> ) in Patients with Chronic Constipation: Combined Results of Three Identical Randomized, Double-Blind, Placebo-Controlled Phase III Trials. <i>Gastroenterology</i> , 2008, 134, A-548.	1.3	6
594	Effects of 5-Hydroxytryptamine (Serotonin) Type 3 Antagonists on Symptom Relief and Constipation in Nonconstipated Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 545-555.	4.4	194

#	ARTICLE	IF	CITATIONS
595	Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation. American Journal of Physiology - Renal Physiology, 2008, 294, G13-G19.	3.4	78
596	Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut, 2008, 57, 1140-1155.	12.1	178
597	Effects of Amitriptyline on Gastric Sensorimotor Function and Postprandial Symptoms in Healthy Individuals: A Randomized, Double-Blind, Placebo-Controlled Trial. American Journal of Gastroenterology, 2008, 103, 2043-2050.	0.4	50
598	High body mass alters colonic sensory-motor function and transit in humans. American Journal of Physiology - Renal Physiology, 2008, 295, G382-G388.	3.4	45
599	Dose-response effect of a $\beta_2$ -adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health. American Journal of Physiology - Renal Physiology, 2008, 294, G1114-G1119.	3.4	28
600	Candidate genes and sensory functions in health and irritable bowel syndrome. American Journal of Physiology - Renal Physiology, 2008, 295, G219-G225.	3.4	58
601	Effects of glucagon-like peptide-1, yohimbine, and nitrenergic modulation on sympathetic and parasympathetic activity in humans. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2008, 295, R874-R880.	1.8	81
602	Consensus Recommendations for Gastric Emptying Scintigraphy: A Joint Report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Journal of Nuclear Medicine Technology, 2008, 36, 44-54.	0.8	295
603	A Placebo-Controlled Trial of Prucalopride for Severe Chronic Constipation. New England Journal of Medicine, 2008, 358, 2344-2354.	27.0	527
604	Pharmacological and non-pharmacological interventions for symptomatic gastroparesis. The Cochrane Library, 2008, , .	2.8	2
605	Probiotics and Irritable Bowel Syndrome. Journal of Clinical Gastroenterology, 2008, 42, S123-S125.	2.2	25
606	New therapeutic approaches in irritable bowel syndrome. European Review for Medical and Pharmacological Sciences, 2008, 12 Suppl 1, 139-40.	0.7	0
607	Effects of Dipeptidyl Peptidase-4 Inhibition on Gastrointestinal Function, Meal Appearance, and Glucose Metabolism in Type 2 Diabetes. Diabetes, 2007, 56, 1475-1480.	0.6	187
608	Nitrenergic contribution to gastric relaxation induced by glucagon-like peptide-1 (GLP-1) in healthy adults. American Journal of Physiology - Renal Physiology, 2007, 292, G1359-G1365.	3.4	24
609	Determination of gastric emptying in nonobese diabetic mice. American Journal of Physiology - Renal Physiology, 2007, 293, G1039-G1045.	3.4	44
610	$\delta$ ligand: a new, smart pill for visceral pain in patients with hypersensitive irritable bowel syndrome?. Gut, 2007, 56, 1337-1338.	12.1	9
611	Effect of different macronutrients in excess on gastric sensory and motor functions and appetite in normal-weight, overweight, and obese humans. American Journal of Clinical Nutrition, 2007, 85, 411-418.	4.7	28
612	The role of peptide YY in integrative gut physiology and potential role in obesity. Current Opinion in Endocrinology, Diabetes and Obesity, 2007, 14, 52-57.	2.3	22

#	ARTICLE	IF	CITATIONS
613	Diabetic Gastroparesis. <i>New England Journal of Medicine</i> , 2007, 356, 820-829.	27.0	301
614	Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 293, G137-G145.	3.4	95
615	Conflicts of Interest and Disclosures in Publications. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 268-273.e1.	4.4	5
616	Efficacy of On-Demand Asimadoline, a Peripheral $\mu$ -Opioid Agonist, in Females With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 1268-1275.	4.4	70
617	A Moveable Feast. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 646-647.	4.4	1
618	Managing Conflict of Interest in Clinical Practice. <i>Mayo Clinic Proceedings</i> , 2007, 82, 607-614.	3.0	30
619	Divergent Views on Managing Clinical Conflicts of Interest—“Reply” <sup>1</sup> . <i>Mayo Clinic Proceedings</i> , 2007, 82, 1014-1015.	3.0	3
620	Alteration of Gastric Functions and Candidate Genes Associated With Weight Reduction in Response to Sibutramine. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 829-837.	4.4	33
621	Functional Dyspepsia: Mechanisms of Symptom Generation and Appropriate Management of Patients. <i>Gastroenterology Clinics of North America</i> , 2007, 36, 649-664.	2.2	23
622	Primary Endpoints for Irritable Bowel Syndrome Trials: A Review of Performance of Endpoints. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 534-540.	4.4	83
623	Alterations in Expression of p11 and SERT in Mucosal Biopsy Specimens of Patients With Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2007, 132, 17-25.	1.3	116
624	Effect of 5 Days Linaclotide on Transit and Bowel Function in Females With Constipation-Predominant Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2007, 133, 761-768.	1.3	234
625	Would Free Fatty Acids Enhance Treatment of Obesity?. <i>Gastroenterology</i> , 2007, 133, 1367-1370.	1.3	4
626	Symptomatic overlap between irritable bowel syndrome and microscopic colitis. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 175-181.	1.9	146
627	Pharmacodynamic effects of a novel prokinetic 5-HT <sub>4</sub> receptor agonist, ATI-7505, in humans. <i>Neurogastroenterology and Motility</i> , 2007, 19, 30-38.	3.0	101
628	Mechanisms of hypersensitivity in IBS and functional disorders. <i>Neurogastroenterology and Motility</i> , 2007, 19, 62-88.	3.0	310
629	Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT <sub>3</sub> antagonist treatment?. <i>Neurogastroenterology and Motility</i> , 2007, 19, 77-84.	3.0	28
630	Appetite and obesity: a gastroenterologist's perspective. <i>Neurogastroenterology and Motility</i> , 2007, 19, 333-341.	3.0	34

#	ARTICLE	IF	CITATIONS
631	Effects of glucagon-like peptide-1 and sympathetic stimulation on gastric accommodation in humans. <i>Neurogastroenterology and Motility</i> , 2007, 19, 716-723.	3.0	18
632	Intestinal permeability and irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2007, 19, 545-552.	3.0	128
633	Effect of the NK3receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans. <i>Neurogastroenterology and Motility</i> , 2007, 19, 732-743.	3.0	41
634	Pharmacogenomics and serotonergic agents: research observations and potential clinical practice implications. <i>Neurogastroenterology and Motility</i> , 2007, 19, 40-45.	3.0	16
635	Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial. <i>Neurogastroenterology and Motility</i> , 2007, 19, 821-830.	3.0	21
636	Clinical application of pharmacogenetics in gastrointestinal diseases. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1857-1869.	1.8	7
637	A Twenty-oneâ€“Yearâ€“Old College Student With Postprandial Regurgitation and Weight Loss. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1314-1317.	4.4	8
638	Gastroenterology and Hepatology Clinical Research Update: 2005â€“2006. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1428-1433.	4.4	4
639	Pharmacological and Pharmacokinetic Aspects of Functional Gastrointestinal Disorders. <i>Gastroenterology</i> , 2006, 130, 1421-1434.	1.3	33
640	Functional Gastrointestinal Disorders. <i>Gastroenterology</i> , 2006, 130, 1466-1479.	1.3	1,740
641	Is There an Association Between GNP3â€“C825T Genotype and Lower Functional Gastrointestinal Disorders?. <i>Gastroenterology</i> , 2006, 130, 1985-1994.	1.3	56
642	Integrated Upper Gastrointestinal Response to Food Intake. <i>Gastroenterology</i> , 2006, 131, 640-658.	1.3	209
643	Obesity Does Not Increase Effects of Synthetic Ghrelin on Human Gastric Motor Functions. <i>Gastroenterology</i> , 2006, 131, 1431-1439.	1.3	45
644	Gastric Sensorimotor Functions and Hormone Profile in Normal Weight, Overweight, and Obese People. <i>Gastroenterology</i> , 2006, 131, 1717-1724.	1.3	97
645	Is there a role for probiotics in irritable bowel syndrome?. <i>Digestive and Liver Disease</i> , 2006, 38, S266-S269.	0.9	14
646	Irritable Bowel Syndrome. <i>Drugs</i> , 2006, 66, 1073-1088.	10.9	64
647	Probiotics and Irritable Bowel Syndrome: Rationale, Putative Mechanisms, and Evidence of Clinical Efficacy. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 264-269.	2.2	102
648	Double-blind, randomized, placebo-controlled study to evaluate the effects of tegaserod on gastric motor, sensory and myoelectric function in healthy volunteers. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 859-867.	3.7	21

#	ARTICLE	IF	CITATIONS
649	Effect of a proton pump inhibitor on postprandial gastric volume, emptying and symptoms in healthy human subjects: a pilot study. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 1037-1043.	3.7	18
650	Effect of atilomotin on gastrointestinal transit in healthy subjects: a randomized, placebo-controlled study. <i>Neurogastroenterology and Motility</i> , 2006, 18, 28-36.	3.0	35
651	Management of patients with chronic abdominal pain in clinical practice. <i>Neurogastroenterology and Motility</i> , 2006, 18, 499-506.	3.0	19
652	Effects of an osmotically active agent on colonic transit.. <i>Neurogastroenterology and Motility</i> , 2006, 18, 300-306.	3.0	21
653	Challenges in drug development for functional gastrointestinal disorders. Part II: Visceral pain. <i>Neurogastroenterology and Motility</i> , 2006, 18, 354-360.	3.0	14
654	New imaging in neurogastroenterology: an overview. <i>Neurogastroenterology and Motility</i> , 2006, 18, 805-812.	3.0	28
655	Effect of female sex hormone supplementation and withdrawal on gastrointestinal and colonic transit in postmenopausal women. <i>Neurogastroenterology and Motility</i> , 2006, 18, 911-918.	3.0	92
656	Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: a randomized, placebo-controlled study. <i>Neurogastroenterology and Motility</i> , 2006, 18, 831-838.	3.0	109
657	Response to letter from Dr Haans and Professor Masclee. <i>Neurogastroenterology and Motility</i> , 2006, 18, 1042-1042.	3.0	2
658	Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 290, G942-G947.	3.4	213
659	Does delayed gastric emptying really cause symptoms in functional dyspepsia?. <i>Gut</i> , 2006, 55, 909-910.	12.1	12
660	Gastroparesis: Clinical Update. CME. <i>American Journal of Gastroenterology</i> , 2006, 101, 1129-1139.	0.4	120
661	A Study of Candidate Genotypes Associated with Dyspepsia in a U.S. Community. <i>American Journal of Gastroenterology</i> , 2006, 101, 581-592.	0.4	114
662	Visceral Hypersensitivity. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, S194-S203.	2.2	50
663	Does the nutrient drink test accurately predict postprandial gastric volume in health and community dyspepsia?. <i>Neurogastroenterology and Motility</i> , 2005, 17, 44-50.	3.0	44
664	Mechanisms in IBS: something old, something new, something borrowed.... <i>Neurogastroenterology and Motility</i> , 2005, 17, 311-316.	3.0	53
665	Alvimopan, a selective peripherally acting $\mu$ -opioid antagonist*. <i>Neurogastroenterology and Motility</i> , 2005, 17, 157-165.	3.0	78
666	A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. <i>Neurogastroenterology and Motility</i> , 2005, 17, 687-696.	3.0	379

#	ARTICLE	IF	CITATIONS
667	Barostat testing of rectal sensation and compliance in humans: comparison of results across two centres and overall reproducibility. <i>Neurogastroenterology and Motility</i> , 2005, 17, 810-820.	3.0	72
668	Effect of Somatostatin Analog on Postprandial Satiating in Obesity. <i>Obesity</i> , 2005, 13, 1572-1579.	4.0	8
669	Gastric Motor and Sensory Functions in Obesity. <i>Obesity</i> , 2005, 13, 491-500.	4.0	85
670	Relationship of gastric emptying and volume changes after a solid meal in humans. <i>American Journal of Physiology - Renal Physiology</i> , 2005, 289, G261-G266.	3.4	46
671	Effect of CCK-1 Antagonist, Dexloxiglumide, in Female Patients with Irritable Bowel Syndrome: A Pharmacodynamic and Pharmacogenomic Study. <i>American Journal of Gastroenterology</i> , 2005, 100, 652-663.	0.4	102
672	Pharmacogenomics and functional gastrointestinal disorders. <i>Pharmacogenomics</i> , 2005, 6, 491-501.	1.3	16
673	Effects of Desipramine and Escitalopram on Postprandial Symptoms Induced by the Nutrient Drink Test in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled Study. <i>Digestion</i> , 2005, 72, 97-103.	2.3	23
674	Principles and Process in the Development of the Mayo Clinic's Individual and Institutional Conflict of Interest Policy. <i>Mayo Clinic Proceedings</i> , 2005, 80, 1340-1346.	3.0	21
675	Effect of Gastric Volume or Emptying on Meal-Related Symptoms After Liquid Nutrients in Obesity: A Pharmacologic Study. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 997-1006.	4.4	60
676	GIH Clinical Research Update: 2004-2005. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 1161-1166.	4.4	0
677	Genetics and Genotypes in Irritable Bowel Syndrome: Implications for Diagnosis and Treatment. <i>Gastroenterology Clinics of North America</i> , 2005, 34, 305-317.	2.2	41
678	Gastric sensory and motor dysfunction in adolescents with functional dyspepsia. <i>Journal of Pediatrics</i> , 2005, 146, 500-505.	1.8	81
679	Effect of Alvimopan and Codeine on Gastrointestinal Transit: A Randomized Controlled Study. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 784-791.	4.4	124
680	Prevalence and Socioeconomic Impact of Upper Gastrointestinal Disorders in the United States: Results of the US Upper Gastrointestinal Study. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 543-552.	4.4	339
681	Association of distinct $\beta_2$ adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders. <i>Gut</i> , 2004, 53, 829-837.	12.1	165
682	Advances in Pharmacological Treatments of IBS. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2004, 39, S766-S767.	1.8	5
683	The Role of Pelvic Floor Dysfunction and Slow Colonic Transit in Adolescents with Refractory Constipation. <i>American Journal of Gastroenterology</i> , 2004, 99, 1579-1584.	0.4	49
684	Is there a SERT-ain association with IBS?. <i>Gut</i> , 2004, 53, 1396-1399.	12.1	45

#	ARTICLE	IF	CITATIONS
685	Effect of oral CCK-1 agonist GI181771X on fasting and postprandial gastric functions in healthy volunteers. <i>American Journal of Physiology - Renal Physiology</i> , 2004, 287, G363-G369.	3.4	45
686	Assessment of gastric accommodation: overview and evaluation of current methods. <i>Neurogastroenterology and Motility</i> , 2004, 16, 275-285.	3.0	112
687	Opioids and the gut: pharmacology and current clinical experience. <i>Neurogastroenterology and Motility</i> , 2004, 16, 383-394.	3.0	193
688	Pathophysiology as a basis for understanding symptom complexes and therapeutic targets. <i>Neurogastroenterology and Motility</i> , 2004, 16, 135-142.	3.0	73
689	Comparison of gastric volumes in response to isocaloric liquid and mixed meals in humans. <i>Neurogastroenterology and Motility</i> , 2004, 16, 567-573.	3.0	33
690	Human enteric neuropathies: morphology and molecular pathology. <i>Neurogastroenterology and Motility</i> , 2004, 16, 515-531.	3.0	200
691	Effect of cyclooxygenase-2 inhibitors on gastric emptying and small intestinal transit in humans. <i>Neurogastroenterology and Motility</i> , 2004, 16, 729-735.	3.0	27
692	Opiates in the control of gastrointestinal tract function: current knowledge and new avenues for research. <i>Neurogastroenterology and Motility</i> , 2004, 16, 67-70.	3.0	7
693	Treating irritable bowel syndrome: overview, perspective and future therapies. <i>British Journal of Pharmacology</i> , 2004, 141, 1237-1248.	5.4	58
694	Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 895-904.	4.4	111
695	Chronic diarrhea: a review on pathophysiology and management for the clinical gastroenterologist. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 198-206.	4.4	48
696	GIH clinical research 2003â€“2004: The year in review. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 1043-1047.	4.4	0
697	A community-based, controlled study of the epidemiology and pathophysiology of dyspepsia. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 985-996.	4.4	140
698	Independent influences of body mass and gastric volumes on satiation in humans. <i>Gastroenterology</i> , 2004, 126, 432-440.	1.3	143
699	Contributions of gastric volumes and gastric emptying to meal size and postmeal symptoms in functional dyspepsia. <i>Gastroenterology</i> , 2004, 127, 1685-1694.	1.3	214
700	Obesity is Associated with Increased Risk of Gastrointestinal Symptoms: A Population-Based Study. <i>American Journal of Gastroenterology</i> , 2004, 99, 1801-1806.	0.4	258
701	The gastrointestinal tract and glucose tolerance. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2004, 7, 479-484.	2.5	32
702	Diagnosis and treatment of enteric neuromuscular diseases. <i>Clinical Autonomic Research</i> , 2003, 13, 10-15.	2.5	23



#	ARTICLE	IF	CITATIONS
703	Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. <i>Neurogastroenterology and Motility</i> , 2003, 15, 79-86.	3.0	209
704	Effects of glucagon-like peptide-1 and feeding on gastric volumes in diabetes mellitus with cardio-vagal dysfunction. <i>Neurogastroenterology and Motility</i> , 2003, 15, 435-443.	3.0	66
705	A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 895-904.	3.7	416
706	Does gall-bladder ejection fraction on cholecystokinin cholescintigraphy predict outcome after cholecystectomy in suspected functional biliary pain?. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 167-174.	3.7	71
707	Effects of asimadoline, a $\mu$ -opioid agonist, on satiation and postprandial symptoms in health. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 507-514.	3.7	41
708	Chronic Constipation. <i>New England Journal of Medicine</i> , 2003, 349, 1360-1368.	27.0	692
709	GI clinical research 2002-2003: the year in review. <i>Clinical Gastroenterology and Hepatology</i> , 2003, 1, 415-420.	4.4	10
710	Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms. <i>Clinical Gastroenterology and Hepatology</i> , 2003, 1, 264-272.	4.4	191
711	Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. <i>Clinical Gastroenterology and Hepatology</i> , 2003, 1, 211-218.	4.4	73
712	Increased caloric intake and decreased postprandial fullness with increased BMI are related to greater fasting gastric volume: A controlled study of 170 volunteers. <i>Gastroenterology</i> , 2003, 124, A31.	1.3	2
713	Fecal Lactoferrin Is A Sensitive and Specific Marker in Identifying Intestinal Inflammation. <i>American Journal of Gastroenterology</i> , 2003, 98, 1309-1314.	0.4	322
714	Functional dyspepsia, upper gastrointestinal symptoms, and transit in children. <i>Journal of Pediatrics</i> , 2003, 143, 609-613.	1.8	68
715	A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2003, 1, 111-121.	4.4	79
716	Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans. <i>Gut</i> , 2003, 52, 1555-1561.	12.1	78
717	Of actors, bolting horses, and drops in oceans!. <i>Gut</i> , 2003, 52, 619-621.	12.1	4
718	Rumination Syndrome in Children and Adolescents: Diagnosis, Treatment, and Prognosis. <i>Pediatrics</i> , 2003, 111, 158-162.	2.1	185
719	Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. <i>American Journal of Physiology - Renal Physiology</i> , 2003, 284, G130-G137.	3.4	109
720	Effects of a $\mu$ -opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. <i>American Journal of Physiology - Renal Physiology</i> , 2003, 284, G558-G566.	3.4	89

#	ARTICLE	IF	CITATIONS
721	Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. <i>Clinical Gastroenterology and Hepatology</i> , 2003, 1, 211-218.	4.4	85
722	Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms. <i>Clinical Gastroenterology and Hepatology</i> , 2003, 1, 264-272.	4.4	145
723	Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms. <i>Clinical Gastroenterology and Hepatology</i> , 2003, 1, 264-72.	4.4	82
724	Anorexia nervosa: manifestations and management for the gastroenterologist. <i>American Journal of Gastroenterology</i> , 2002, 97, 255-269.	0.4	36
725	Serotonergic modulation of visceral sensation: lower gut. <i>Gut</i> , 2002, 51, i81-i86.	12.1	72
726	Testing the sensitivity hypothesis in practice: tools and methods, assumptions and pitfalls. <i>Gut</i> , 2002, 51, i34-i40.	12.1	56
727	Motilin agonists and dyspepsia: throwing out the baby with the bath water. <i>Gut</i> , 2002, 51, 612-613.	12.1	25
728	SPECT imaging of the stomach: comparison with barostat, and effects of sex, age, body mass index, and fundoplication. <i>Gut</i> , 2002, 51, 781-786.	12.1	195
729	Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. <i>Gastroenterology</i> , 2002, 123, 425-432.	1.3	261
730	AGA technical review on irritable bowel syndrome. <i>Gastroenterology</i> , 2002, 123, 2108-2131.	1.3	1,247
731	Drugs targeting functional bowel disorders: lessons from drug trials. <i>Current Opinion in Pharmacology</i> , 2002, 2, 684-690.	3.5	10
732	Irritable bowel syndrome: newer pharmacological agents acting on the gut. <i>International Congress Series</i> , 2002, 1241, 143-148.	0.2	1
733	Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. <i>American Journal of Physiology - Renal Physiology</i> , 2002, 282, G424-G431.	3.4	162
734	Effects of 5-HT <sub>3</sub> antagonism on postprandial gastric volume and symptoms in humans. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 225-233.	3.7	50
735	Consensus report: clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 1407-1430.	3.7	106
736	Performance characteristics of scintigraphic transit measurements for studies of experimental therapies. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 1781-1790.	3.7	170
737	Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus. <i>Neurogastroenterology and Motility</i> , 2002, 14, 123-131.	3.0	106
738	A nutrient drink test to assess maximum tolerated volume and postprandial symptoms: effects of gender, body mass index and age in health. <i>Neurogastroenterology and Motility</i> , 2002, 14, 249-253.	3.0	113

#	ARTICLE	IF	CITATIONS
739	Review : Noninvasive Measurement of Gastric Accommodation by SPECT. Korean Journal of Internal Medicine, 2002, 17, 1-6.	1.7	7
740	Gender differences in irritable bowel syndrome. Journal of Gender-specific Medicine, 2002, 5, 37-45.	0.1	19
741	Advances in diabetic gastroparesis. Reviews in Gastroenterological Disorders, 2002, 2, 47-56.	0.6	27
742	Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology, 2001, 120, 354-360.	1.3	278
743	Management of the irritable bowel syndrome. Gastroenterology, 2001, 120, 652-668.	1.3	299
744	Reliability of a semi-automated analysis to measure gastric accommodation using SPECT in humans. Gastroenterology, 2001, 120, A287.	1.3	13
745	Effects of an $\alpha_2$ -adrenergic agonist on gastrointestinal transit, colonic motility, and sensation in humans. American Journal of Physiology - Renal Physiology, 2001, 281, G1468-G1476.	3.4	70
746	A Randomized Controlled Clinical Trial of the Serotonin Type 3 Receptor Antagonist Alosetron in Women With Diarrhea-Predominant Irritable Bowel Syndrome. Archives of Internal Medicine, 2001, 161, 1733.	3.8	275
747	Tegaserod. Alimentary Pharmacology and Therapeutics, 2001, 15, 277-289.	3.7	172
748	What is the Relevance of a Systematic Review of Pharmacological Management in Irritable Bowel Syndrome to Older People?. Journal of the American Geriatrics Society, 2001, 49, 1249-1252.	2.6	0
749	Pharmacological modulation of human gastric volumes demonstrated noninvasively using SPECT imaging. Neurogastroenterology and Motility, 2001, 13, 533-542.	3.0	43
750	Validation of a stable isotope gastric emptying test for normal, accelerated or delayed gastric emptying. Neurogastroenterology and Motility, 2001, 13, 567-574.	3.0	91
751	Enteric nervous system disorders: genetic and molecular insights for the neurogastroenterologist. Neurogastroenterology and Motility, 2001, 13, 277-295.	3.0	42
752	Adynamic ileus in severe Guillain-Barré syndrome. Muscle and Nerve, 2001, 24, 963-965.	2.2	59
753	Is There a Role for Gastric Accommodation and Satiety in Asymptomatic Obese People?. Obesity, 2001, 9, 655-661.	4.0	64
754	Visceral hypersensitivity: facts, speculations, and challenges. Gut, 2001, 48, 125-131.	12.1	176
755	An Open Trial of Octreotide Long-Acting Release in the Management of Short Bowel Syndrome. American Journal of Gastroenterology, 2001, 96, 1494-1498.	0.4	71
756	Noninvasive measurement of gastric accommodation in patients with idiopathic nonulcer dyspepsia. American Journal of Gastroenterology, 2001, 96, 3099-3105.	0.4	143

#	ARTICLE	IF	CITATIONS
757	Paraneoplastic Gastrointestinal Motor Dysfunction: Clinical and Laboratory Characteristics. <i>American Journal of Gastroenterology</i> , 2001, 96, 373-379.	0.4	150
758	Gender-related differences in slowing colonic transit by a 5-HT <sub>3</sub> antagonist in subjects with diarrhea-predominant irritable bowel syndrome. <i>American Journal of Gastroenterology</i> , 2001, 96, 2671-2676.	0.4	105
759	Effect of Glucagon-Like Peptide-1(7-36)-Amide on Initial Splanchnic Glucose Uptake and Insulin Action in Humans With Type 1 Diabetes. <i>Diabetes</i> , 2001, 50, 565-572.	0.6	53
760	Adynamic ileus in severe Guillain-Barré syndrome. <i>Muscle and Nerve</i> , 2001, 24, 963-965.	2.2	1
761	SPECT test to measure gastric accommodation validated with simultaneous barostat measurement. <i>Gastroenterology</i> , 2001, 120, A97-A97.	1.3	4
762	Pathophysiology in irritable bowel syndrome. <i>Drug News and Perspectives</i> , 2001, 14, 268.	1.5	12
763	Dyspepsia, irritable bowel syndrome, and constipation: review and what's new. <i>Reviews in Gastroenterological Disorders</i> , 2001, 1, 2-17.	0.6	3
764	Towards identifying optimal doses for alpha <sub>2</sub> adrenergic modulation of colonic and rectal motor and sensory function. <i>Alimentary Pharmacology and Therapeutics</i> , 2000, 14, 783-793.	3.7	65
765	Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2000, 14, 869-878.	3.7	54
766	New therapies for functional bowel diseases. <i>Current Gastroenterology Reports</i> , 2000, 2, 355-363.	2.5	3
767	Novel Testing of Human Gastric Motor and Sensory Functions: Rationale, Methods, and Potential Applications in Clinical Practice. <i>American Journal of Gastroenterology</i> , 2000, 95, 3365-3373.	0.4	83
768	Toward Office-Based Measurement of Gastric Emptying in Symptomatic Diabetics Using [13C]Octanoic Acid Breath Test. <i>American Journal of Gastroenterology</i> , 2000, 95, 2751-2761.	0.4	66
769	Serotonin: A Mediator of The Brain-Gut Connection. <i>American Journal of Gastroenterology</i> , 2000, 95, 2698-2709.	0.4	369
770	Psychological Disorders in Patients With Evacuation Disorders and Constipation in A Tertiary Practice. <i>American Journal of Gastroenterology</i> , 2000, 95, 1755-1758.	0.4	84
771	A valid, accurate, office based non-radioactive test for gastric emptying of solids. <i>Gut</i> , 2000, 46, 768-773.	12.1	78
772	Effects of a serotonin 5-HT <sub>4</sub> receptor antagonist SB-207266 on gastrointestinal motor and sensory function in humans. <i>Gut</i> , 2000, 47, 667-674.	12.1	80
773	Coloanal motor coordination in association with high-amplitude colonic contractions after pharmacological stimulation. <i>American Journal of Gastroenterology</i> , 2000, 95, 715-719.	0.4	42
774	Gastrointestinal Tract Symptoms Among Persons With Diabetes Mellitus in the Community. <i>Archives of Internal Medicine</i> , 2000, 160, 2808.	3.8	228

#	ARTICLE	IF	CITATIONS
775	Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. <i>Lancet, The</i> , 2000, 355, 1035-1040.	13.7	517
776	Economic Burden of Irritable Bowel Syndrome. <i>Pharmacoeconomics</i> , 2000, 17, 331-338.	3.3	88
777	Pharmacology and clinical experience with alosetron. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 147-159.	4.1	28
778	Recombinant human neurotrophin-3 increases noncholinergic smooth muscle contractility and decreases nonadrenergic noncholinergic (NANC) inhibition of myenteric neurons in guinea-pig colon. <i>Gastroenterology</i> , 2000, 118, A710.	1.3	5
779	Neurogastroenterology: evolving concepts and techniques to study motility and hypersensitivity. <i>Digestive and Liver Disease</i> , 2000, 32, 227-232.	0.9	1
780	Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans. <i>Gastroenterology</i> , 2000, 119, 41-50.	1.3	158
781	Alosetron. <i>Drugs</i> , 2000, 59, 519-520.	10.9	1
782	Ten secrets for development of drugs for functional gastrointestinal diseases. <i>Gastroenterology</i> , 2000, 118, 653.	1.3	14
783	Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. <i>Gastroenterology</i> , 2000, 118, 463-468.	1.3	386
784	Serotonin: a mediator of the brain-gut connection. <i>American Journal of Gastroenterology</i> , 2000, 95, 2698-2709.	0.4	213
785	Functional bowel disease: roles of sensation and motility. <i>Swiss Medical Weekly</i> , 2000, 130, 1772-81.	1.6	3
786	Development of a test to measure gastric accommodation in humans. <i>American Journal of Physiology - Renal Physiology</i> , 1999, 277, G1217-G1221.	3.4	87
787	Motor Function in Irritable Bowel Syndrome. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 1999, 13, 8A-11A.	1.7	21
788	Audit of the Treatment of Malnutrition Due to Chronic Intestinal Pseudo-Obstruction With Enteral Nutrition. <i>Nutrition in Clinical Practice</i> , 1999, 14, 29-32.	2.4	6
789	Selective stimulation of colonic transit by the benzofuran 5HT <sub>4</sub> agonist, prucalopride, in healthy humans. <i>Gut</i> , 1999, 44, 682-686.	12.1	203
790	INTESTINAL PSEUDO-OBSTRUCTION. <i>Annual Review of Medicine</i> , 1999, 50, 37-55.	12.2	87
791	The Effects of Biofeedback on Rectal Sensation and Distal Colonic Motility in Patients With Disorders of Rectal Evacuation. <i>American Journal of Gastroenterology</i> , 1999, 94, 751-756.	0.4	28
792	Review article: clinical evidence to support current therapies of irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 48-53.	3.7	31

#	ARTICLE	IF	CITATIONS
793	Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT <sub>3</sub> receptor antagonist. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 1149-1159.	3.7	342
794	Near-total completion gastrectomy for severe postvagotomy gastric stasis: analysis of early and long-term results in 62 patients. <i>Journal of Gastrointestinal Surgery</i> , 1999, 3, 15-23.	1.7	86
795	Gastric accommodation in non-ulcer dyspepsia and the roles of <i>Helicobacter pylori</i> infection and vagal function. <i>Gut</i> , 1999, 44, 55-64.	12.1	150
796	Descending Perineum Syndrome: Audit of Clinical and Laboratory Features and Outcome of Pelvic Floor Retraining. <i>American Journal of Gastroenterology</i> , 1999, 94, 126-130.	0.4	104
797	Mitochondrial neurogastrointestinal encephalomyopathy: Manometric and diagnostic features. <i>Gastroenterology</i> , 1999, 116, 959-963.	1.3	54
798	Modulation of gastric sensory and motor functions by nitrenergic and $\beta$ -adrenergic agents in humans. <i>Gastroenterology</i> , 1999, 116, 573-585.	1.3	171
799	The effects of biofeedback on rectal sensation and distal colonic motility in patients with disorders of rectal evacuation Evidence of an inhibitory rectocolonic reflex in humans?. <i>American Journal of Gastroenterology</i> , 1999, 94, 751-756.	0.4	47
800	Review article: clinical evidence to support current therapies of irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13 Suppl 2, 48-53.	3.7	5
801	Clinical subgroups of chronic constipation: exploring the potential of polyethylene glycol. <i>Italian Journal of Gastroenterology and Hepatology</i> , 1999, 31 Suppl 3, S253-4.	0.5	0
802	Review article: colonic sensorimotor physiology in health, and its alteration in constipation and diarrhoeal disorders. <i>Alimentary Pharmacology and Therapeutics</i> , 1998, 12, 287-302.	3.7	79
803	Measurement of gastrointestinal motility in the GI laboratory. <i>Gastroenterology</i> , 1998, 115, 747-762.	1.3	317
804	What's in a name? Roll on Rome II. <i>Gastroenterology</i> , 1998, 114, 237.	1.3	13
805	Reproducibility and Simplification of <sup>13</sup> C-Octanoic Acid Breath Test for Gastric Emptying of Solids. <i>American Journal of Gastroenterology</i> , 1998, 93, 92-98.	0.4	114
806	Clinical and Upper Gastrointestinal Motility Features in Systemic Sclerosis and Related Disorders. <i>American Journal of Gastroenterology</i> , 1998, 93, 1085-1089.	0.4	151
807	Medium term effects of a new 5HT <sub>3</sub> antagonist, alosetron, in patients with carcinoid diarrhoea. <i>Gut</i> , 1998, 42, 628-634.	12.1	41
808	Rectal tone, distensibility, and perception: reproducibility and response to different distensions. <i>American Journal of Physiology - Renal Physiology</i> , 1998, 274, G584-G590.	3.4	90
809	Behavioral Intervention for the Treatment of Rumination. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1998, 27, 596-598.	1.8	47
810	Irritable bowel syndrome: A technical review for practice guideline development. <i>Gastroenterology</i> , 1997, 112, 2120-2137.	1.3	521

#	ARTICLE	IF	CITATIONS
811	Rapid Gastric Emptying in Patients With Functional Diarrhea. <i>Mayo Clinic Proceedings</i> , 1997, 72, 323-328.	3.0	36
812	[13C]octanoic acid breath test for gastric emptying of solids: Accuracy, reproducibility, and comparison with scintigraphy. <i>Gastroenterology</i> , 1997, 112, 1155-1162.	1.3	187
813	Adrenergic modulation of human colonic motor and sensory function. <i>American Journal of Physiology - Renal Physiology</i> , 1997, 273, G997-G1006.	3.4	106
814	Review article: irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 1997, 11, 3-15.	3.7	346
815	A pilot study of motility and tone of the left colon in patients with diarrhea due to functional disorders and dysautonomia. <i>American Journal of Gastroenterology</i> , 1997, 92, 297-302.	0.4	57
816	SDZ HTF 919 stimulates canine colonic motility and transit in vivo. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1997, 280, 1270-6.	2.5	69
817	Simplifying the evaluation of postprandial antral motor function in patients with suspected gastroparesis. <i>American Journal of Gastroenterology</i> , 1997, 92, 1496-500.	0.4	41
818	Pharmacological modulation of rectal tone alters perception of distention in humans. <i>American Journal of Gastroenterology</i> , 1997, 92, 2073-9.	0.4	51
819	Colonic transit scintigraphy labeled activated charcoal compared with ion exchange pellets. <i>Journal of Nuclear Medicine</i> , 1997, 38, 1807-10.	5.0	83
820	Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome. <i>American Journal of Gastroenterology</i> , 1997, 92, 2250-6.	0.4	16
821	Hyperventilation alters colonic motor and sensory function: Effects and mechanisms in humans. <i>Gastroenterology</i> , 1996, 111, 368-377.	1.3	23
822	Relation between fat malabsorption and transit abnormalities in human carcinoid diarrhea. <i>Gastroenterology</i> , 1996, 110, 405-410.	1.3	8
823	Antral axial forces postprandially and after erythromycin in organic and functional dysmotilities. <i>Digestive Diseases and Sciences</i> , 1996, 41, 697-704.	2.3	10
824	Symptomatic improvement with one-year cisapride treatment in neuropathic chronic intestinal dysmotility.. <i>Alimentary Pharmacology and Therapeutics</i> , 1996, 10, 403-409.	3.7	21
825	Motility and tone of the left colon in constipation: a role in clinical practice?. <i>American Journal of Gastroenterology</i> , 1996, 91, 2532-8.	0.4	68
826	Ascending Colon Response to Feeding: Evidence for a 5-Hydroxytryptamine-3 Mechanism. <i>Scandinavian Journal of Gastroenterology</i> , 1995, 30, 562-567.	1.5	20
827	Differences in colonic tone and phasic response to a meal in the transverse and sigmoid human colon.. <i>Gut</i> , 1995, 37, 264-269.	12.1	117
828	Differential regional effects of octreotide on human gastrointestinal motor function.. <i>Gut</i> , 1995, 36, 743-748.	12.1	94

#	ARTICLE	IF	CITATIONS
829	The rumination syndrome: Clinical features rather than manometric diagnosis. <i>Gastroenterology</i> , 1995, 108, 1024-1029.	1.3	142
830	Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with type II diabetes mellitus. <i>Gastroenterology</i> , 1995, 109, 755-765.	1.3	160
831	Psychosensory modulation of colonic sensation in the human transverse and sigmoid colon. <i>Gastroenterology</i> , 1995, 109, 1772-1780.	1.3	159
832	Scintigraphy of the Whole Gut: Clinical Evaluation of Transit Disorders. <i>Mayo Clinic Proceedings</i> , 1995, 70, 113-118.	3.0	92
833	Audit of constipation in a tertiary referral gastroenterology practice. <i>American Journal of Gastroenterology</i> , 1995, 90, 1471-5.	0.4	117
834	Evaluation of an inexpensive screening scintigraphic test of gastric emptying. <i>Journal of Nuclear Medicine</i> , 1995, 36, 93-6.	5.0	65
835	The surgeon's role in the treatment of chronic intestinal pseudoobstruction. <i>American Journal of Gastroenterology</i> , 1995, 90, 2147-51.	0.4	63
836	Effect of octreotide on gastrointestinal pressure profiles in health and in functional and organic gastrointestinal disorders.. <i>Gut</i> , 1994, 35, 1064-1069.	12.1	58
837	Serotonergic mediation of postprandial colonic tonic and phasic responses in humans.. <i>Gut</i> , 1994, 35, 536-541.	12.1	121
838	Comparison of the postural tachycardia syndrome (POTS) with orthostatic hypotension due to autonomic failure. <i>Journal of the Autonomic Nervous System</i> , 1994, 50, 181-188.	1.9	91
839	A 5HT <sub>3</sub> antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea. <i>Gastroenterology</i> , 1994, 106, 1184-1189.	1.3	67
840	Determinants of response to a prokinetic agent in neuropathic chronic intestinal motility disorder. <i>Gastroenterology</i> , 1994, 106, 916-923.	1.3	49
841	Clinical Management of Intractable Constipation. <i>Annals of Internal Medicine</i> , 1994, 121, 520.	3.9	115
842	Comparison of simultaneous recordings of human colonic contractions by manometry and a barostat. <i>Neurogastroenterology and Motility</i> , 1994, 6, 213-222.	3.0	33
843	Idiopathic autonomic neuropathy. <i>Neurology</i> , 1994, 44, 1675-1675.	1.1	158
844	Appraisal of medium- and long-term treatment of gastroparesis and chronic intestinal dysmotility. <i>American Journal of Gastroenterology</i> , 1994, 89, 1769-74.	0.4	24
845	A patient with localized megacolon and intractable constipation: evidence for impairment of colonic muscle tone. <i>American Journal of Gastroenterology</i> , 1994, 89, 1867-70.	0.4	11
846	Small bowel motility disorders. <i>Revista De GastroenterologÃa De MÃ©xico</i> , 1994, 59, 120-6.	0.2	3



#	ARTICLE	IF	CITATIONS
847	Use of gastroduodenal manometry to differentiate mechanical and functional intestinal obstruction: an analysis of clinical outcome. <i>American Journal of Gastroenterology</i> , 1994, 89, 339-44.	0.4	51
848	Study of human gastroduodenojejunal motility. <i>Digestive Diseases and Sciences</i> , 1993, 38, 785-794.	2.3	74
849	Autonomic dysfunction in patients with chronic intestinal pseudo-obstruction. <i>Clinical Autonomic Research</i> , 1993, 3, 95-100.	2.5	46
850	Motor Dysfunction of the Small Bowel and Colon in Patients with the Carcinoid Syndrome and Diarrhea. <i>New England Journal of Medicine</i> , 1993, 329, 1073-1078.	27.0	165
851	Chronic Diarrhea in Diabetes Mellitus: Mechanisms and an Approach to Diagnosis and Treatment. <i>Mayo Clinic Proceedings</i> , 1993, 68, 691-702.	3.0	99
852	Autonomic dysfunction in gastrointestinal motility disorders.. <i>Gut</i> , 1993, 34, 397-401.	12.1	127
853	Effect of a 5HT <sub>3</sub> antagonist (ondansetron) on rectal sensitivity and compliance in health and the irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 1993, 7, 543-551.	3.7	83
854	The current role of erythromycin in the clinical management of gastric emptying disorders. <i>American Journal of Gastroenterology</i> , 1993, 88, 169-71.	0.4	39
855	Control of muscle tone in the human colon.. <i>Gut</i> , 1992, 33, 541-546.	12.1	84
856	Human gastric and jejunal transit and motility after Roux gastrojejunostomy. <i>Gastroenterology</i> , 1992, 103, 1133-1143.	1.3	73
857	Towards a relatively inexpensive, noninvasive, accurate test for colonic motility disorders. <i>Gastroenterology</i> , 1992, 103, 36-42.	1.3	119
858	Transit through the proximal colon influences stool weight in the irritable bowel syndrome. <i>Gastroenterology</i> , 1992, 102, 102-108.	1.3	186
859	Measurement of Small Bowel and Colonic Transit: Indications and Methods. <i>Mayo Clinic Proceedings</i> , 1992, 67, 1169-1179.	3.0	68
860	The Irritable Bowel Syndrome: Mechanisms and a Practical Approach to Management. <i>Annals of Internal Medicine</i> , 1992, 116, 1001-1008.	3.9	115
861	Antroduodenal manometry. <i>Digestive Diseases and Sciences</i> , 1992, 37, 1305-1308.	2.3	3
862	Neurohormonal Factors in Functional Dyspepsia: Insights on Pathophysiological Mechanisms. <i>Gastroenterology</i> , 1991, 100, 1311-1318.	1.3	140
863	Enteric neuronal autoantibodies in pseudoobstruction with small-cell lung carcinoma. <i>Gastroenterology</i> , 1991, 100, 137-142.	1.3	241
864	Gastrointestinal motor dysfunction in acquired selective cholinergic dysautonomia associated with infectious mononucleosis. <i>Gastroenterology</i> , 1991, 100, 252-258.	1.3	83

#	ARTICLE	IF	CITATIONS
865	Variation of muscle tone in the human colon. <i>Gastroenterology</i> , 1991, 101, 373-381.	1.3	131
866	Scintigraphic measurement of regional gut transit in idiopathic constipation. <i>Gastroenterology</i> , 1991, 101, 107-115.	1.3	251
867	Towards a less costly but accurate test of gastric emptying and small bowel transit. <i>Digestive Diseases and Sciences</i> , 1991, 36, 609-615.	2.3	188
868	Long-term efficacy of oral cisapride in symptomatic upper gut dysmotility. <i>Digestive Diseases and Sciences</i> , 1991, 36, 616-620.	2.3	127
869	Familial enteric neuropathy with pseudoobstruction. <i>Digestive Diseases and Sciences</i> , 1991, 36, 1168-1171.	2.3	25
870	The Relationship Between Clinical Factors and Gastrointestinal Dysmotility in Diabetes Mellitus. <i>Neurogastroenterology and Motility</i> , 1991, 3, 268-272.	3.0	19
871	The ileocecal Area and the Irritable Bowel Syndrome. <i>Gastroenterology Clinics of North America</i> , 1991, 20, 297-311.	2.2	12
872	Neurohormonal factors in functional dyspepsia: insights on pathophysiological mechanisms. <i>Gastroenterology</i> , 1991, 100, 1311-8.	1.3	44
873	Acute and chronic intestinal pseudo-obstruction. <i>Advances in Internal Medicine</i> , 1991, 36, 287-306.	0.9	13
874	The ileocecal area and the irritable bowel syndrome. <i>Gastroenterology Clinics of North America</i> , 1991, 20, 297-311.	2.2	6
875	Stasis Syndromes Following Gastric Surgery. <i>Journal of Clinical Gastroenterology</i> , 1990, 12, 505-512.	2.2	90
876	Ileocolonic transfer of solid chyme in small intestinal neuropathies and myopathies. <i>Gastroenterology</i> , 1990, 99, 158-164.	1.3	74
877	Idiopathic autonomic denervation in eight patients presenting with functional gastrointestinal disease. <i>Digestive Diseases and Sciences</i> , 1990, 35, 609-616.	2.3	72
878	Transit of solids through the human colon: regional quantification in the unprepared bowel. <i>American Journal of Physiology - Renal Physiology</i> , 1990, 258, G856-G862.	3.4	91
879	Disorders of Gastrointestinal Motility in Neurologic Diseases. <i>Mayo Clinic Proceedings</i> , 1990, 65, 825-846.	3.0	84
880	Stasis syndromes following gastric surgery: clinical and motility features of 60 symptomatic patients. <i>Journal of Clinical Gastroenterology</i> , 1990, 12, 505-12.	2.2	24
881	Human gastric emptying and colonic filling of solids characterized by a new method. <i>American Journal of Physiology - Renal Physiology</i> , 1989, 257, G284-G290.	3.4	128
882	Jejunal manometry in distal subacute mechanical obstruction: significance of prolonged simultaneous contractions. <i>Gut</i> , 1989, 30, 468-475.	12.1	77

#	ARTICLE	IF	CITATIONS
883	Autonomic function and motility in intestinal pseudoobstruction caused by paraneoplastic syndrome. <i>Digestive Diseases and Sciences</i> , 1989, 34, 1937-1942.	2.3	75
884	Motility disorders and stress. <i>Digestive Diseases and Sciences</i> , 1989, 34, 1777-1786.	2.3	71
885	Chronic Intestinal Pseudo-Obstruction: Diagnosis and Treatment. <i>Mayo Clinic Proceedings</i> , 1989, 64, 60-70.	3.0	60
886	Abnormal postcibal antral and small bowel motility due to neuropathy or myopathy in systemic sclerosis. <i>Gastroenterology</i> , 1989, 96, 110-115.	1.3	140
887	Effect of six weeks of treatment with cisapride in gastroparesis and intestinal pseudoobstruction. <i>Gastroenterology</i> , 1989, 96, 704-712.	1.3	153
888	Effect of six weeks of treatment with cisapride in gastroparesis and intestinal pseudoobstruction. <i>Gastroenterology</i> , 1989, 96, 704-12.	1.3	122
889	Disorders of small intestinal motility. <i>Gastroenterology Clinics of North America</i> , 1989, 18, 405-24.	2.2	11
890	Colectomy for severe constipation. <i>Digestive Diseases and Sciences</i> , 1988, 33, 1196-1196.	2.3	1
891	Chronic idiopathic intestinal pseudo-obstruction: clinical and intestinal manometric findings.. <i>Gut</i> , 1987, 28, 5-12.	12.1	288
892	Gastric electromechanical and neurohormonal function in anorexia nervosa. <i>Gastroenterology</i> , 1987, 93, 958-965.	1.3	210
893	Dose-related effects of synthetic human beta-endorphin and naloxone on fed gastrointestinal motility. <i>American Journal of Physiology - Renal Physiology</i> , 1986, 251, G147-G154.	3.4	27
894	Pyloric dysfunction in diabetics with recurrent nausea and vomiting. <i>Gastroenterology</i> , 1986, 90, 1919-1925.	1.3	396
895	Relationship between impaired gastric emptying and abnormal gastrointestinal motility. <i>Gastroenterology</i> , 1986, 91, 94-99.	1.3	266
896	Impaired transit of chyme in chronic intestinal pseudoobstruction. <i>Gastroenterology</i> , 1986, 91, 619-626.	1.3	137
897	Brainstem tumor presenting as an upper gut motility disorder. <i>Gastroenterology</i> , 1985, 89, 1411-1414.	1.3	47
898	Gastrointestinal motility disturbances in patients with orthostatic hypotension. <i>Gastroenterology</i> , 1985, 88, 1852-1859.	1.3	86
899	Relation between antral motility and gastric emptying of solids and liquids in humans. <i>American Journal of Physiology - Renal Physiology</i> , 1985, 249, G580-G585.	3.4	150
900	Abnormal intestinal motility in diabetics with the gastroparesis syndrome. <i>European Journal of Clinical Investigation</i> , 1984, 14, 420-427.	3.4	308

#	ARTICLE	IF	CITATIONS
901	Pseudodominant Transmission of Fructose Intolerance in an Adult and Three Offspring. <i>New England Journal of Medicine</i> , 1982, 307, 537-540.	27.0	26
902	Pharmacological inhibition of chenodeoxycholate-induced fluid and mucus secretion and mucosal injury in the rabbit colon. <i>Digestive Diseases and Sciences</i> , 1982, 27, 865-869.	2.3	25
903	Dose-related effects of chenodeoxycholic acid in the rabbit colon. <i>Digestive Diseases and Sciences</i> , 1980, 25, 433-438.	2.3	60
904	Dysmotility of the Small Intestine and Colon. , 0, , 1108-1156.		2
905	Cystic Diseases of the Liver and Biliary Tract. , 0, , 361-367.		1
906	Acute Viral Hepatitis. , 0, , 374-386.		1
907	Gastrointestinal Dilation and Stent Placement. , 0, , 643-663.		1
908	Liver: Anatomy, Microscopic Structure, and Cell Types. , 0, , 50-57.		1
909	Dysmotility of the Small Intestine and Colon. , 0, , 295-310.		2
910	Tumors of the Small Intestine. , 0, , 202-207.		0
911	Computed Tomography of the Gastrointestinal Tract. , 0, , 756-767.		0
912	Complications of AIDS and Other Immunodeficiency States. , 0, , 501-508.		0
913	Helminthic Infections of the Gastrointestinal Tract and Liver. , 0, , 524-543.		0
914	Endoscopic Retrograde Cholangiopancreatography: Diagnostic and Therapeutic. , 0, , 634-642.		0
915	Approach to the Patient with Ascites and Its Complications. , 0, , 447-458.		0
916	Obesity: Treatment and Complications. , 0, , 491-494.		0
917	Esophageal Neoplasms. , 0, , 93-101.		0
918	Gastrointestinal Manifestations of Systemic Diseases. , 0, , 544-553.		0

#	ARTICLE	IF	CITATIONS
919	Radiation Injury in the Gastrointestinal Tract. , 0, , 597-602.		0
920	Endoscopic Mucosal Biopsy: Histopathological Interpretation. , 0, , 878-930.		0
921	Miscellaneous diseases of the small intestine. , 0, , 208-215.		0
922	Diseases of the Peritoneum, Retroperitoneum, Mesentery, and Omentum. , 0, , 484-490.		0
923	Positron Emission Tomography in the Gastrointestinal Tract. , 0, , 782-803.		0
924	Endoscopic Diagnosis and Treatment of Nonvariceal Upper Gastrointestinal hemorrhage. , 0, , 675-679.		0
925	Primary Sclerosing Cholangitis and Other Cholangiopathies. , 0, , 354-360.		0
926	Abdominal Angiography. , 0, , 820-841.		0
927	The Effect of Caloric Intake and Macronutrient Composition on Intestinal Cholesterol Absorption and Bile Acids in Patients with Obesity. American Journal of Physiology - Renal Physiology, 0, , .	3.4	2